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 Alzheimer’s disease (AD) is the sixth leading cause of death in United States, affecting 
more than five million people every year. Despite substantial research into the topic, including 
over a hundred thousand research papers on the topic and nearly a billion dollars per year in 
funding, no drugs have been approved by the FDA to prevent, slow, or cure AD. Upon discovering 
that patients with Alzheimer’s disease had increased Cyclophilin D (CypD), a key mitochondrial 
matrix protein responsible for the initiation of mitochondrial apoptosis, we generated models of 
tau-induced AD with altered CypD expression. CypD overexpression (OE) mice were successfully 
used to model more severe AD pathology. These mice showed increased levels of 
hyperphosphorylated tau (HPT). Additionally, these mice showed mitochondrial failure in an age 
dependent manner. Synaptic and neuronal loss were also identified in an age dependent manner. 
Finally, cognitive impairments were detected using an open field study and a daily task 
performance study. CypD knock out (KO) mice were used to model the potential therapeutic 
effects of lowering CypD in an AD model. These mice showed an amelioration of every AD 
biomarker tested. CypD KO mice showed lower HPT loads and normalized mitochondrial 
function. There was no detectable loss of synaptic terminals in the CypD KO line, and there was 
no loss of cognitive function in either open field or a daily task performance test. 
 A small molecule CypD inhibitor created in our lab was used in a tau-induced model of 
AD to attempt to create the significant improvements seen with genetic ablation of CypD. This 
compound was determined to be safe for use in mice after testing in cell cultures revealed that it 
was non-toxic and effective at preventing Aβ-induced cellular death. In mice, the CypD inhibitor 
reduced HPT accumulation, restored mitochondrial function, and prevented cognitive declines 
without inducing any apparent toxicity in the mice. 
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 We identified that CypD played a similarly important role in non-transgenic aging mice. 
Non-transgenic mice show signs of decline with aging. By 24 months, mice show increases in 
anxiety and decreases in daily task performance. These can be explained by increased 
mitochondrial failure and reactive oxygen species production. CypD OE mice not crossed into any 
AD model show an advanced aging phenotype in which the previously identified biomarkers of 
aging mice present stronger and at an earlier time point. CypD KO mice not crossed into any AD 
model show an amelioration of all aging-related cognitive dysfunction and molecular failures 
measured. 
 Overall, these studies point to an important role of CypD in both aging- and AD-induced 
cognitive impairments through the restoration of mitochondrial function and the preservation of 
synapses. These studies also establish our small molecule CypD inhibitor as an effective method 
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Chapter 1 Introduction 
Alzheimer’s disease 
Alzheimer’s disease (AD) is the most common cause of dementia [1], affecting one in six 
adults over the age of 65, and one in three over the age of 85. Sporadic AD makes up 90 to 98% 
of all AD cases, with early onset familial Alzheimer’s disease as a result of genetic mutations in 
presenilins being less common [1]. More than 5 million Americans were living with AD in 2016, 
and that number is expected to grow to as many as 13.8 million people by 2050. AD is 
characterized by several common cognitive, behavioral, and psychological symptoms which 
include memory loss, confusion, difficulty with self-care, and depression. The socioeconomic cost 
of AD is enormously high, costing $236 billion in payments to American health care providers 
alone, representing 1.3% of the USA GDP [2]. In 2015, an additional $221.3 billion worth of care 
was provided by unpaid family caregivers. Despite this impact, AD remains the only top 10 cause 
of death with no treatment to cure or even delay disease progression [3].  
Aging is the top risk factor for developing AD, as well as a high risk factor for the 
development of cancer [4-6], type 2 diabetes [7, 8], cardiovascular disease [9, 10], stroke [11, 12], 
and Parkinson’s disease [13, 14]. Healthy aging in the absence of any diagnosable neurocognitive 
disease is associated with cognitive decline. In a longitudinal study of 1,721 adults tested for visual 
memory and crystallized intelligence (an example would be nice as this is not a common term), an 
increasing rate of decline correlated with age, particularly from 65-74 years of age [15]. The exact 
cause of these losses are unknown, but researchers have hypothesized neuronal loss and lowered 
neuronal conduction speeds may explain the deficits. However, while loss of cerebral volume is 
associated with aging, neuronal loss is not, disproving hypotheses attributing cognitive loss to 
neuronal death [16]. Research currently suggests that loss of synapses, rather than entire neurons, 
is responsible for the cortical thinning and the accompanying cognitive deficits seen with age. In 
2 
 
healthy aging, brain volumes can be reduced by 0.5%-1% each year. Synaptic loss is accompanied 
by changing dendritic strength and length, as well as reduced myelinated axon length [17]. It is 
likely then that the root cause of memory loss in healthy elderly populations is synaptic loss and 
reductions in signal strength due to demyelination. 
Biochemically, AD is characterized by accumulations of amyloid-beta (Aβ) (Figure 1-1 
A,D), increases in hyperphosphorylated tau (HPT) (Figure 1-1 B,E), and hypometabolism (Figure 
1-2 A,B) [18], which have led to three major hypotheses of AD development that will be discussed 
here.  
 
Figure 1-1: AD is marked by accumulation of Aβ plaques and tau tangles 
A) Plaques in the frontal cortex are stained with Haemotoxylin and Eosin. B) Tangles are stained 
with H&E in the hippocampus. C) Silver staining can identify both Aβ plaques and tau tangles. 
D) Antibodies specific to Aβ mark plaques. E) Specific antibodies mark Tau tangles. F) Lewy 
bodies can be identified with H&E staining in the cortex. [19] 
3 
 
Amyloid Cascade Hypothesis 
 Amyloid precursor protein (APP) is a ubiquitously expressed membrane protein that 
appears to be involved in cell growth and neuronal process outgrowth, but researchers have failed 
to identify specific functions. Once embedded in the membrane, several processing pathways exist 
for APP based primarily on how the protein is localized. In the AD pathway, APP is cleaved 
sequentially by β-secretase and γ-secretase to produce Aβ fragments 1-40 and 1-42, with Aβ 1-42 
considered more toxic [20]. Aβ fragments can exist as monomers, dimers, filaments/oligomers, or 
insoluble plaques. While it is the insoluble plaques that are necessary for diagnosing a patient with 
AD, smaller, soluble Aβ conformations are likely more toxic [21]. Aβ accumulations are difficult 
for the cell to degrade and often disrupt cytosolic degradation on a large scale, as well as disrupting 
cell signaling. The amyloid cascade hypothesis depends on the appearance of Aβ plaques that 
appear long before hyperphosphorylated tau filaments (HTF), described later in detail. In human 
tissue, animal models, and various cell lines, Aβ plaques have been proven to cause disruption of 
cellular membranes, induce mitochondrial DNA mutations, decrease metabolism of glucose, 
decrease electron transport chain (ETC) activity, increase reactive oxygen species (ROS), disrupt 
long term potentiation (LTP), and disrupt calcium homeostasis and calcium buffering [22-25]. 
These sweeping alterations to cell physiology have supported the amyloid hypothesis as they 
indicate a causative role. 
 The amyloid hypothesis is further buoyed by research into familial AD, which is always 
caused by mutations in genes related to APP and amyloid processing. Specifically, familial AD is 
caused by mutations in APP, Presenilin-1 (PS1), or Presenilin-2 (PS2), with PS1 mutations being 
the most common. PS1 and PS2 make up the core of the γ-secretase unit that cleaves APP. The 
genetic disruption of these proteins always leads to early onset, or familial, AD [26].  
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  Many experiments have demonstrated that the addition of Aβ to cellular and animal 
systems results in AD-like phenotypes, giving credence to the amyloid cascade hypothesis [27-
30]. However, over 50 drugs have been shown  to modify Aβ deposition, accumulation, and the 
resulting neuronal damage, none have succeeded in passing through clinical trials [31]. Most often, 
these drugs have failed for lack of efficacy rather than due to safety concerns. 
 With the creation of the Pittsburg Compound B to stain Aβ plaques under positron emission 
tomography [32-36], it was determined that Aβ accumulations are found in a small percentage of 
brains of cognitively normal, adults of advanced age [37]. This suggested to some researchers that 
these plaques precede the cognitive symptoms of AD that are usually used for diagnosis [35, 36, 
38-42], while others interpreted this as a negation of the amyloid cascade [43]. For the former 
scientists, the early deposition of Aβ indicated a need for earlier screening and treatment of 
patients. For the latter scientists, the early appearance of Aβ without symptoms suggested that 
other proteins may play a larger role in AD.  
Tau hypothesis 
Tau is a microtubule-associated protein that promotes neuronal process outgroWTh during 
development, giving neurons polarity. In developed neurons, tau binds to microtubules, providing 
stability [44-48]. Tau also supports membrane interactions and cellular trafficking [44], giving tau 
an important function in microtubule dynamics. Microtubule dynamics are integral in synapse 
formation and pruning, both are essential functions for learning [49]. Despite these important roles, 
genetic ablation of tau creates no overt phenotype; this is likely due to a striking upregulation of 
microtubule-associated protein 1A, which can assume the functional role of tau with only minimal 
reorganization of the microtubules [50]. A later study of the same model identified that axonal 
trafficking was slower and axonal groWTh was reduced in the tau knock-out (KO) model, although 
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these factors did not give rise to a behavioral or disease phenotype [51]. The role of tau in 
trafficking is of heightened importance in the brain, where proteins and organelles, including 
mitochondria, must be trafficked from the soma to the synaptic terminals. 
Tau contains 79 serine and threonine residues [52, 53] and four tyrosine residues that 
provide sites capable of undergoing phosphorylation , meaning that 20% of the protein is made up 
of amino acids with potential for phosphorylation [54, 55]. Studying these phosphorylation sites 
has proved to be difficult owing to the need for specific antibodies to differentiate between 
phosphorylation sites that are often very similar in structure [55]. Additionally, because there are 
several different protein domains with phosphorylatable sites, researchers have assumed that 
phosphorylation in different regions cannot be considered to have the same effect [56]. However, 
despite these difficulties, repeated experiments have shown hyperphosphorylation of tau in 
pathological conditions [44, 45, 54, 57, 58]. 
Because HPT does not efficiently bind to microtubules, HPT impairs microtubule 
formation and induces destabilization after formation [58-60]. OutgroWTh of neuronal processes 
can be affected by HPT, but because AD is an aging disease, there is little effect on the outgroWTh 
of axons in this condition, since outgroWTh happens embryonically.  
HPT, once dissociated from the microtubule, dimerizes to form paired helical fragments, 
which then group to form hyperphosphorylated tau filaments (HTF) [61, 62]. HTFs show 
phosphorylation at 45 of the possible sites, compared to 15 phosphorylated sites in control tau [63-
66]. The driving force behind this rampant increase in phosphorylation is unknown, but researchers 
have observed that many of these sites may be transiently phosphorylated and then rapidly 
dephosphorylated in cognitively normal, human patients. Rapid dephosphorylation can be blocked 
by inhibitors of Ser/Thr phosphatases. Some researchers hypothesize that HPT is not the result of 
increased phosphorylation, but rather a decrease in dephosphorylation. Additionally, the build-up 
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of HPT favors dimerization and eventual HTF formation due to an inability to efficiently degrade 
the hyperphosphorylated form [52]. 
 While Aβ appears before HTFs, concentration and location of HTFs appears to better 
correlate to disease progression, which in combination with the studies that identify Aβ in the 
absence of cognitive impairment, led some researchers to support the tau hypothesis over the 
amyloid cascade hypothesis. In animal models, mutation of tau can result in AD-like symptoms 
[67]. However, some studies have identified HTFs in asymptomatic patients [68]. 
Mitochondrial cascade hypothesis 
In a healthy human, 20% of the ingested glucose is required for energy metabolism in the 
brain [69, 70]. This is due to the high energetic baseline to generate the ATP required for basic 
neuronal activity. Maintaining proper membrane polarization is particularly important in neurons, 
which are routinely depolarized and must be rapidly repolarized as the neuron fires, in addition to 
a series of housekeeping requirements [71]. Additional energy is also necessary to modulate the 
transport of biomolecules down extended axonal processes, as well as maintaining synaptic 
functioning [72-76]. Mitochondria must regularly change size and shape to meet these needs 
through a process known as mitochondrial dynamics, including fission and fusion, both of which 
are energetic processes [77-82]. 
Fusion and fission allow the mitochondria to meet the bioenergetic needs of the cell while 
also replacing mitochondria functioning at suboptimal capacity. This process is commonly 
referred to as mitochondrial dynamics and is thought to be a controlling factor in neuronal health 
and survival [83]. Mitochondrial dynamics are tightly controlled by multiple proteins, and 
evidence in several models demonstrates that disturbing the homeostasis of any of these protein-
enzyme interactions results in neurodegeneration [84-87]. Disrupted mitochondrial dynamics is an 
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early sign of mitochondrial dysfunction in AD [77, 78, 88, 89]. To test whether traditional 
hallmarks of AD could disrupt mitochondrial dynamics, M17 neuroblastoma cells were cultured 
with APP, which could reliably induce altered mitochondrial morphology and distribution 
throughout the cell. This effect was ameliorated by the addition of a β-secretase inhibitor [90]. 
Lastly, Aβ has been identified to accumulate in mitochondria before cytosolic plaques have formed 
in human patients [91-93] and in mouse models [24, 94-96]. This data demonstrates the importance 
of proper fusion and fission to maintain neurons in a non-degenerative state, and also demonstrates 
that Aβ can be a causative factor in mitochondrial dysfunction. 
 
Figure 1-2: Hypometabolism in Alzheimer’s disease [97]. 
A) A normal individual and B) B individual at high risk for AD [97]. 
 
 Neither the amyloid cascade hypothesis nor the tau hypothesis generated the development 
of any FDA approved drugs in several decades of research, despite many drugs targeted at 
reduction of the accumulation of these proteins [98]. Better imaging technologies led to the 
development of the mitochondrial hypothesis. As shown in Figure 1-2, PET scans and fMRIs 
reveal that hypometabolism is established before Aβ plaques or HTFs [99], and hypometabolism 
predicts the appearance of Aβ and HPT. Hypometabolism in the brain was a better predictor of 
8 
 
cognitive dysfunction than the appearance of Aβ or HPT [100] since mitochondrial malfunction 
produces ROS, which increases the accumulation of both Aβ and HTFs. 
Mitochondrial dysfunction is present in the most popular animal models of AD [101, 102]. 
The 3xTg-AD model was generated by creating mutations in the APP protein, PS1 protein, and 
tau protein [103], and is one of the most common mouse models to study  AD  [104-107], This 
model showed reduced mitochondrial respiration rates in 3-month-old female mice. Decreased 
mitochondrial function was assessed by measuring the expression of the pyruvate dehydrogenase 
complex and cytochrome c oxidation. This phenotype appeared four months before Aβ pathology 
appeared and ten months before tau pathology occurred. In this model, embryonic hippocampal 
neurons also displayed a significant decrease in mitochondrial respiration [108]. At three months, 
3xTg-AD mice showed significantly more oxidative stress, as marked by increased lipid 
peroxidation and decreased levels of antioxidants glutathione and vitamin E [109]. These studies 
demonstrate that mitochondrial dysfunction is an early factor in models of AD pathology. 
Synaptic mitochondria are particularly important in maintaining neuronal health, and 
several models have shown that impaired trafficking of mitochondria to the synapses results in 
neuronal death despite the mitochondria of the soma being fully functional [110]. For this reason, 
researchers began to study synaptic and non-synaptic mitochondria as separate pools which 
revealed pathology critical to AD. In mice overexpressing human APP, synaptic mitochondria 
showed impaired function by four months of age, compared to the non-synaptic mitochondria from 
the same animals and synaptic mitochondria from wild-type animals. Supporting this finding, Aβ 
accumulation occurred in synaptic mitochondria of transgenic (Tg) mice earlier than in non-
synaptic mitochondria of Tg mice or synaptic mitochondria of non-Tg mice [111, 112]. This 
indicates that in AD pathology, synaptic mitochondria are among the first to be affected. Impaired 
synaptic mitochondrial function has been found to reduce synaptic plasticity in the earliest stages 
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of AD in several models [113, 114], providing a mechanism by which mitochondrial function may 
create the behavioral phenotype associated with AD.  
In addition to synaptic mitochondria being more strongly affected and disrupted earlier in 
the progression of AD, several studies demonstrate that fewer mitochondria are targeted to the 
synapses [115]. In rodent models of AD expressing either human APP or tau, time-lapse imaging 
in primary neurons shows that mitochondria move more slowly and often have altered patterns of 
movement when compared to mitochondria in wild-type neurons [84, 116]. It would be over-
simplistic to say that in healthy neurons, mitochondria move quickly along microtubule 
scaffolding while they do not move or move slowly in degenerating neurons. Rather, in healthy 
neurons, mitochondrial movements can be classified into five basic patterns based on 
combinations of starting, stopping, and moving distances of hundreds of microns, with all of these 
patterns being normal. In healthy neurons, mitochondria can move at a velocity of several microns 
per second and commonly change directions [117]. Current tracking technology does not allow 
for the tagging and monitoring of an individual mitochondrion; such technology would allow 
researchers to observe where a specific mitochondrion was moving, and from this data garner 
information about why mitochondria appear to be in nearly constant motion [118].  
Despite not being able to track individual mitochondria, it has been possible to determine 
reasons for abnormal trafficking in AD models. Reduced expression of dynamin like protein 1 
(DLP1), is seen in AD patients, and results in more mitochondria distributed into the soma, as well 
as higher productions of ROS. DLP1 depletion in a cell model results in mitochondrial trafficking 
disruptions and mitochondrial dysfunction, similar to that observed in traditional AD models. The 
addition of DLP1 to the system rescues mitochondrial distribution [119]. Treatments in AD that 
target the mitochondria will require understanding why and how fewer mitochondria are targeted 
to the synapse. Further, developing mitochondrial based therapeutics will be benefited by 
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understanding the mechanism by which synaptic mitochondria undergo more stress than somatic 
mitochondria. 
Replicating what was seen in animal and cellular models, mitochondria numbers are 
significantly reduced in the affected brain regions of AD patients, such that it is unlikely that the 
neuron could support its bioenergetic needs [120]. Mitochondria that are present appear to be 
significantly damaged, with ruptured inner membranes, lipofuscin-filled vacuoles (a marker of 
“wear and tear” [121]), and variable mitochondrial DNA content [122]. Respiration in AD tissues 
shows a two-thirds reduction compared to age-matched controls [87]. Together, these human, 
animal, and cell studies suggest that mitochondrial deficits are key in AD pathology, but they are 
insufficient to determine a chain of events in AD pathology. 
In determining how mitochondrial bioenergetics and ROS production affected amyloid 
load, a model of AD mice overexpressing APP was crossed with mice heterozygous for superoxide 
dismutase 2 (SOD2) KO  [123]. SOD2 clears ROS produced by the electron transport chain [124]. 
Homozygotes for SOD2 KO in addition to the APP overexpression were embryonically lethal, 
while heterozygotes for SOD2 KO were not. When SOD2 heterozygotes were treated with 
antioxidants, several dose-dependent effects were seen. First, with the higher dose of antioxidant 
drug, lower Aβ loads were seen. Second, in the heterozygous mice receiving the low dose of 
antioxidants, significant tau phosphorylation was observed [123]. This study functionally and 
causally links mitochondrial health and ROS production to the common biomarkers of AD.  
Interactions between Tau and Mitochondria 
HPT has been shown to interact with mitochondria in several different conditions [125]. 
Based on molecular modeling, it was suspected that a motif on the N-terminus was responsible for 
this interaction [126]. A truncated form of tau containing only the N-terminus region was found 
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to localize to the mitochondrial matrix [127], where it impaired oxidative phosphorylation by 
blocking the adenine nucleotide translocator (ANT), resulting in mitochondrial fragmentation and 
elevated oxidative stress [125]. To more fully investigate this phenomenon, patient-derived Aβ 
oligomer extracts were cultured with rat embryonic hippocampal slices. Mitochondrial 
dysfunction and apoptosis were observed despite the concentration of Aβ being predicted to be 
too low to cause significant damage. HPT was found in these slices, leading researchers to 
determine that low-level Aβ was sufficient to drive the formation of HPT, which then imposed a 
significant negative effect on mitochondria, specifically the ANT, eventually triggering apoptosis 
[128]. 
In addition to impacting bioenergetics, tau and Aβ has been found to impact the 
mitochondrial proteome. In 6-month-old male 3xTg-AD mice, expression of 23 mitochondrial 
proteins differed significantly between transgenic and non-transgenic mice [129]. The affected 
proteins were involved in a variety of mitochondrial maintenance and energy production pathways. 
In a similar assay of hippocampal tissue from three other AD mouse models (P301L, APP(sw), 
and PS2-N1411), 24 proteins related to mitochondria were dysregulated. Eight of these proteins 
were related to complex I and complex IV. The P301L model of AD is driven by a single tau 
mutation [130]. This model showed increased dysfunction of complex I while the APP(sw) model 
showed increased dysfunction of complex IV [131] indicating that tau and Aβ have specific effects 
on the mitochondria. Further mechanistic understanding of how early stage APP and tau mutations 
cause dysregulation of the mitochondrial proteome may reveal a mechanism by which these AD-
related mutations impair metabolism. 
P301L tau mice were used to study the tau-dependent changes in axonal transport in a 
system free of Aβ plaques. The mutant tau was sufficient to form extensive HPT deposits, but did 
not form HTFs. Despite this, mitochondrial trafficking was impacted in 8-11 month old mice. In 
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these younger mice, the number of mitochondria moving in the anterograde direction (from the 
cell body to the synapse) was significantly increased. However, by 23-24 months, this effect was 
reversed and there were significantly less mitochondria moving to the synapse in the P301L mutant 
mice [132]. This study causatively shows that increased tau, specifically HPT, impairs 
mitochondrial transport to the synapse. As mitochondrial density at the synapse is reduced in AD, 
this link to tau is important in understanding how to increase bioenergetics at the synapse. The 
authors chose not to speculate on the increased anterograde transport of mitochondria in young 
mice, but when one considers this data in conjunction with previously proposed models of early 
mitochondrial deficits at the synapse, the inevitable hypothesis is that the increased transport of 
mitochondria to the synapse reflects a compensatory mechanism to prevent synaptic loss. 
Current therapeutic targets in AD 
 Currently, there are five drugs approved for the treatment of AD which can be divided into 
two categories: cholinesterase inhibitors and N-methyl D-aspartate (NMDA) antagonists. All of 
these drugs target the symptoms of AD: memory loss and cognitive confusion. 
 The goal of medicating those with AD is not to attempt to cure the disease or extend the 
patients lifespan. More accurately, these drugs preserve some independent function for a short 
period of time and are typically e effective for less than a year. 
Cholinesterase inhibitors 
 Cholinesterase is an enzyme that works by hydrolyzing the ester bond on acetylcholine, 
breaking the neurotransmitter down into choline and acetic acid. Acetylcholine is an excitatory 
neurotransmitter, and its degradation via cholinesterase allows neurons to return to resting states. 
Cholinesterase inhibitors prevent these actions, allowing for increased neuronal signaling [133].  
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Three cholinesterase inhibitors have been approved: Aricept, Exelon, and Razadyne. 
Aricept is approved for all stages of AD, while Exelon and Razadyne are approved only for mild 
to moderate AD. Cholinesterase inhibitors share a common list of side effects that tend to be very 
rare: nausea, vomiting, loss of appetite, and increased bowel movements. However, for most 
people these side effects are not severe [134]. 
Due to their shared mechanism of action regarding inhibition of cholinesterase, switching 
between these drugs does not provide further benefit for a patient, but patients may respond to one 
drug over another. What this means functionally, is that once the best drug for that patient has 
stopped having an effect, switching drugs will likely not cause any improvements in 
symptomology [134]. 
However, while all drugs inhibit cholinesterase as their main function, each drug does have 
slightly different mechanisms of action. Exelon prevents the breakdown of butyrylcholine, a 
synthetic compound similar to acetylcholine. Razadyne, in addition to inhibiting cholinesterase, 
stimulates nicotinic receptors to release more acetylcholine [134]. 
NMDA antagonists 
 Memantine is approved for moderate to severe AD. It is less frequently prescribed due to 
its more severe side effects, including headache, constipation, confusion, and dizziness. These side 
effects are slightly more severe than those from the cholinesterase inhibitors [134]. 
 Inhibiting NMDA receptors reduces glutamate toxicity in AD. Glutamate can bind to 
multiple receptor types, including α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) receptors. However, NMDA receptors were targeted in AD therapeutics due to the 
posited role of NMDA receptors in learning and memory. Glutamate binds to NMDA receptors 
and triggers an influx of calcium (Ca2+) ions [135]. NMDA receptors are unique in their relatively 
large influx of Ca2+ ions [136]. 
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 NMDA receptors have a unique function in learning and memory due to the role of 
Magnesium (Mg2+) gating. Simplistically, NMDA receptors are blocked by Mg2+ at the neuron’s 
resting potential. Upon the activation of Long Term Potentiation (LTP), consistent glutamate 
release stimulates AMPA receptors, removing the Mg2+. This allows the activation of NMDA 
receptors and the resulting Ca2+ cascade, including activation of Ca2+/calmodulin-dependent 
protein kinase II (CaMKII) which modulates synaptic integrity. Thus, NMDA receptors have an 
established role in learning and memory [137]. 
 Despite the importance of NMDA receptors in LTP, an excess of glutamate signaling can 
cause toxicity. Glutamate toxicity was initially termed excitotoxicity, a term still often found in 
AD literature [138-140]. Glutamate toxicity leads to a loss of post synaptic structures, and neurons 
appear to be more sensitive to glutamate-induced synaptic loss [141]. The presence of Aβ 
enhanced NMDA signaling [142], increased glutamate release from nearby microglia [142], and 
decreased clearing of glutamate [143]. Glutamate toxicity is thought to be mediated by high Ca2+ 
concentration in the cytosol [144-147]. Excessive calcium in the cytosol triggers apoptosis [148], 
disrupts the mitochondria [149], and perturbs cell signaling [150]. Therefore, Memantine works 
to suppress excessive NMDA activation that leads to high Ca2+ levels resulting in neuronal death.
  
Combination drugs 
A drug trademarked Namzaric combines Aricept and Memantine to inhibit cholinesterase 
and NMDA receptors. Namzaric, like Memantine, is approved only for moderate to severe AD. 
However, it has significant side effects from both classes of drugs [134]. 
Molecular targets in the interaction of tau and mitochondria 
Taking together the data presented herein, the link between HPT, mitochondrial 
dysfunction, and the AD phenotype is clear. However, despite over 20 years of research, these 
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interactions have not translated into clinically useful drugs. As drug development continues, there 
has been some progress in developing drug targets. 
Mitochondrial dysfunction, in addition to leading to increased ROS levels and reducing the 
bioenergetic output, can induce apoptosis through opening of the mitochondrial permeability 
transition pore (mPTP) [151]. Several groups have sought to target this mechanism in hopes of 
preventing apoptosis. In order to understand how to pharmacologically intervene in this system, a 
brief description of the initiation of apoptosis is necessary (for a full review see reference [90]). 
While apoptosis can follow two basic pathways (extrinsic and intrinsic), it is the intrinsic pathway, 
also called the mitochondrial pathway, that poses an interesting drug target. Apoptosis is initiated 
through the binding of pro-apoptotic proteins to anti-apoptotic proteins to alleviate their self-
inhibition. Mitochondria sequester these pro-apoptotic proteins to allow for careful control of this 
system while the anti-apoptotic proteins exist in the cytosol. A Ca2+ signal triggers the opening of 
the mPTP [152, 153], releasing cytochrome C (Cyt C) and multiple other pro-apoptotic proteins 
into the cytosol where Cyt C then binds to apoptotic protease activating factor 1 to induce the 
formation of the apoptosome, thereby activating caspase-9 and caspase-3/7. Caspases perform a 
variety of tasks in initiating apoptosis including the upregulation of DNA cleaving enzymes and 
cleaving proteins essential for DNA and nuclear stability, ultimately leading to cell death [154]. 
In addition to the pro-apoptotic proteins, mitochondria release a large amount of Ca2+, which works 
to sensitize pro-apoptotic factors [155]. In order to fully understand the workings of the mPTP, a 
brief explanation of cyclophilins is required. 
Cyclophilins 
Cyclophilins are a class of proteins that were discovered and named from the identification 
of their peptidyl prolyl cis/trans isomerases (PPIase) enzyme activity [156, 157]. The role of a 
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PPIase enzyme is to stabilize the cis to trans conformational switch for proline residues. The 
cis/trans switch is necessary for the stability of many proteins [158]. Although structures vary 
between isoforms, all Cyclophilins have a conserved domain of 109 amino acids responsible for 
their PPIase activity [159-162]. Cyclophilins have been identified in mammals, plants, insects, 
fungi, and bacteria [161, 162]. Mammals have 7 cyclophilins that differ by structure, cellular 
location, and specific function. 
 Cyclophilin A (CypA) was the first identified cyclophilin [157]. It is cytosolic and found 
in all mammals [163]. Structurally, CypA is formed by an eight-stranded beta-barrel with two 
alpha-helices [164, 165].  
 Functionally, CypA has been identified as important for the folding of neuronal receptors 
[166]. CypA further regulates transcription factors, including Zpr1, likely through a stabilization 
method [167]. CypA has been indicated in T cell activation via regulation of interleukin 2 [168-
170], which may be responsible for its role in infection of human immunodeficiency virus (HIV) 
[171-177]. 
CypA has the highest affinity for Cyclosporine A (CsA), which binds to a hydrophobic 
core of 7 amino acids [164, 165]. CsA works through the formation of a complex with CypA and 
binds to calcineurin, a calcium activated protein phosphatase. This complex blocks the 
translocation of nuclear factor of activated T cells from the cytosol to the nucleus, which prevents 
the transcription of interleukin-2 [178, 179]. The overall effect of this action is immune 
suppression, which allows CsA to be used as an immunosuppressant during organ transplantation. 
Further, CsA binds to calcineurin, creating a stable complex and reducing the effectiveness of 
cleavage by proteases. CypA-CsA-calcineurin has reduced phosphatase activity, altering calcium 
homeostasis in cells [178, 180-182]. 
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Cyclophilin B (CypB) is very similar in structure to CypA [183], but is located in the 
endoplasmic reticulum (ER) [162, 163]. While less is known about CypB than CypA, CypB 
creates complexes with the peptide hormone prolactin to induce transcription [184]. CypB further 
governs the activation of interferon-regulatory factor 3, which induces interferon β upon 
translocation to the nucleus [185]. 
Cyclophilin C (CypC) is structurally homologous to CypA and CypB [186], and shares 
CypB’s location in the ER [162, 163], where it regulates transcription factors. 
Cyclophilin D (CypD) has more unique morphology and is the only cyclophilin located in 
the mitochondria [187, 188]. Due to its unique position and functions, more attention will be given 
to CypD later in the review. 
Cyclophilin E (CypE) is an understudied cyclophilin located in the nucleus. Studies suggest 
that CypE helps to regulate DNA-binding proteins [189]. 
Cyclophilin 40 (Cyp40) has a similar structure to CypA, CypB, and CypC. However, 
Cyp40 has a series of tetratricopeptide repeats, similar to those seen in stress response proteins 
[190]. Cyp40 is located in the cytoplasm [190], where it forms complexes with steroid receptors 
[191, 192]. Cyp40 has been found to form a dimeric complex with heat shock protein 90 (HSP 90) 
[191, 192], which further supports hypotheses that Cyp40 is involved in the heat shock response 
pathway. Several studies identified Cyp40 as a regulator of the c-Myb gene via its PPIase activity 
[193, 194]. C-Myb binds to heat shock transcription factor 3, which induces the expression of heat 
shock protein 70 (HSP 70). 
CypNK, the first identified cyclophilin in natural killer cells, is the largest cyclophilin [195, 
196] and is located in the cytoplasm [195, 196].  
Several cyclophilins exhibit catalytic degradation of DNA based on stimulation by calcium 
or magnesium [197]. CypA and CypB are best stimulated by a combination of both calcium and 
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magnesium, while CypC can be stimulated by magnesium alone [198]. Active CypA, CypB, and 
CypC degrade apoptotic DNA [187].  
Cyclophilin D 
 Encoded by the PPif gene, CypD is sometimes referred to as Cyclophilin F. However, for 
the purpose of these studies, CypD will be used. CypD is a cyclophilin unique to mammals [199] 
that is sensitive to calcium fluctuations [200]. 
 CypD is comprised of 178 amino acids [201] and forms up to four protein-protein hydrogen 
bonds. The structure is considered rigid and does not change a considerably upon binding to 
partners like CsA. CypD has 8 anti-parallel beta pleated sheets and two alpha helices formed 
against the sheets. A short alpha helical turn houses the active residue Trp121 [202]. The PPIase 
region is composed of catalytic arginine (Arg55) and hydrophobic, aromatic, and polar residues 
[202]. The back face of CypD exhibits protein-protein interactions [203].  
 The most important identified role for CypD is triggering the opening of the mPTP. 
Previous hypotheses identified the structure of the mPTP as the ANT in the mitochondrial inner 
membrane and the voltage-dependent anion channel (VDAC) in the outer membrane [204]. 
However, with the technology to create genetically modified experimental animals, these 
hypotheses lost credence. KO of ANT did not reduce mPTP formation [205]. KO of VDAC 
similarly did not affect mPTP formation [206]. Binding studies identified phosphate carrier (PiC) 
as a binding partner of CypD, which lead to hypotheses that PiC may be involved in forming the 
mPTP. However, PiC KO did not prevent mPTP opening. Interestingly, PiC KO did slightly 
change electrochemical dynamics of the mPTP opening, indicating that PiC may still have a 
regulatory role [207].  
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 More recently, dimers of ATP synthase have been hypothesized to from the mPTP [208]. 
In isolated membrane fractions, dimers of ATP synthase form a pore of similar conductance to the 
mPTP. Additionally, the oligomycin sensitivity-conferring protein (OSCP) unit of ATP synthase 
has been identified as a binding partner of CypD [209]. With age and increases in CypD 
expression, binding becomes irregular and leads to mitochondrial damage [210-212]. 
Like other cyclophilins, CypD interacts with CsA with high affinity (KD=13.4nM) [213]. 
CsA has a broad range of effects on cytosolic Cyclophilins. CsA binding to CypD prevents the 
opening of the mPTP [203]. Experimentally, CsA has become the gold standard positive control 
blocking the mPTP. CsA inhibits the PPIase activity of CypD [214], but it is unknown if this is 
functionally important to the opening of the mPTP. CsA binding improves the ability of 
mitochondria to buffer calcium in vitro and ex vivo [200]. 
 CypD does not require PPIase activity to open the mPTP. Experimentally, sangliferin A 
can inhibit mPTP opening, but does not alter PPIase activity [215]. CypD has been classified as a 
redox sensor, which is intimately linked to the opening of the mPTP [216]. Under standard 
conditions, a disulfide bridge forms between Cys203 and Cys157, but this bridge can be disrupted 
by redox modulation. Cys203 is required for mPTP opening [217], which links functional redox 
sensing with mPTP opening. The disulfide bridge appears to block the binding site of CypD to the 
OSCP region in mitochondrial climates of low ROS. With high levels of ROS, the disulfide bridge 
is disrupted, allowing CypD to bind to the OSCP and open the mPTP. Further levels of precise 
control are offered by the S-nitrosylation of Cys203, which changes mPTP dynamics by making 
mitochondria more resistant to hydrogen peroxide induced opening [217]. 
 Experimental models show that CypD triggers an opening of the mPTP in conditions of 
cellular or tissue stress, like high levels of calcium or ROS [217]. However, the precise molecular 
pathway by which this signaling occurs is still unknown. About 1% of active glycogen synthase 
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kinase 3 beta (GSK3β) is translocated to the mitochondria where it phosphorylates CypD at Ser38, 
Ser39, or Ser123. Phosphorylation at these sites leads to the induction of the mPTP [218]. Another 
route may be via p53, which can translocate to the mitochondrial matrix and has been detected 
after ischemia as a complex with CypD. The p53-CypD complexing is eliminated by CsA, 
indicating that CsA and p53 share a binding site. The p53-CypD complex is not affected by 
calcium induced mPTP opening [219]. 
Cyclophilin D in Alzheimer’s disease 
 Aβ has been hypothesized to drive the formation of ROS through disruption of the ETC 
[220] and inhibition of ATP synthase [221, 222]. Aβ has been shown to prompt the opening of the 
mPTP [23, 223-227]. With the recent hypothesis that ATP synthase makes up the core of the 
mPTP, these observations link Aβ-induced ROS production directly to the mPTP, leading to 
research on the direct connections between Aβ and the mPTP. 
 In brain regions high in Aβ, CypD expression is elevated in both human patients (Figure 
1-3) [23] and mouse models of AD [24]. In tissue from human patients and animal models of AD, 
Aβ was found to colocalize with CypD, and binding studies found that the two form a complex in 
the mitochondrial matrix [24]. This is specific to Aβ, as reverse sequence peptides do not 
colocalize with CypD or form a complex. In binding studies of CypD and the OSCP, Aβ enhances 




Figure 1-3: CypD expression in AD patients [229] 
 In a human-APP overexpression model of AD, CypD KO improved many metrics of the 
AD phenotype [23, 24], including calcium buffering capacity and calcium homeostasis, reduced 
mitochondrial swelling in response to calcium toxicity, improved mitochondrial membrane 
potential resistance, reduced super oxide production, ameliorated ATP levels and ETC activity, 
improved learning and memory dysfunction, normalized LTP, normalized neuronal trafficking 
[230], normalized ATP synthase activity[210], and improved intracellular signaling [231]. These 
promising results indicate that CypD should be targeted in AD therapies. 
Inhibition of Cyclophilin D 
 Inhibition of CypD by CsA is not indicated in most neurodegenerative diseases due to the 
chronic nature of the disease that would create problems with CsA toxicity. Additionally, CsA 
cannot cross the blood brain barrier, which is necessary for the treatment of most 
neurodegenerative conditions. Thus, it has been necessary to design new small molecule 
compounds that are not toxic, have the ability to cross the blood brain barrier, and inhibit CypD in 
a specific manner. 
 A screening library of compounds that have been modeled based on the structure of CypD 
and satisfy Lepinsky’s rule of five have been created for this purpose [232-234]. These compounds 
have all been modeled to cross the blood brain barrier. From this library, several compounds have 
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been successful in blocking mPTP opening without causing cellular toxicity. One has been tested 
in Aβ induced cell toxicity and can prevent cellular death. A pyrazinyl urea-based mPTP blocker 
has been found to be more efficient at preventing mPTP opening upon Aβ insult than CsA [235].  
 SS31, a cell membrane antioxidant, has been identified as an effective method of reducing 
CypD expression which reduced mPTP opening. SS31 treatment in AD models rescued learning 
and memory deficits and ameliorated the loss of synaptic proteins [236]. 
Several groups are attempting to develop drugs to prevent tau aggregation, which 
elucidates an earlier stage of tau-mitochondrial dysfunction. One such drug is thionine, and its 
more recently formulated derivative methylthioninium chloride (MTC), which inhibits tau-tau 
interactions [237, 238]. This drug has been criticized as being likely to inhibit microtubule 
assembly by blocking tau-microtubule binding [152, 239]. At 50 µM MTC, approximately 50% 
of microtubule assembly formation is inhibited, while the clinically necessary concentration to 
inhibit the formation of tau aggregates would be 0.2-0.4 µM. This data means that the chance of 
MTC inhibiting microtubule binding in a clinically relevant way is not significant [240]. 
A variant of MTC with better bioavailability (leuco-methylthioninium with a counter-ion, 
LMTX) is currently being tested in phase 3 clinical trials. Three hundred and twenty-one 
individuals participated in the phase 2 trials, for which a significant improvement over the placebo 
group was found in brain activity based on a Single Photon Emission Computed Tomography 
(SPECT) scan. A SPECT scan produces images similar to a PET scan, albeit at a lower resolution, 
for significantly less monetary investment; PET scan is the recommended functional imaging tool 
for diagnosis of AD [241]. Due to the decreased resolution and contrast, a subgroup of results was 
validated with PET scans. These results were significant at 50 weeks in both mild and moderate 
cognitive impairment [242]. Despite this promising ability to inhibit tau aggregates and improve 
phenotype, there are still off-target effects that would need to be addressed, including the increased 
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rate of β-oxidation in the mitochondria and inhibition of monoamine oxidase A, both of which 
could have severe phenotypic consequences regarding metabolism and mood alterations [240]. 
Overall, while there are several promising targets, more work is needed to ensure that there is a 
therapeutic option for AD that is effective with minimal side effects. 
Animal Models Available for the Study of Alzheimer’s disease 
 Most research in AD is done in rodent animal models, although some models have been 
created in Drosophila, Caenorhabditis elegans, and other mammals. 171 rodent models exist, 5 of 
which are rat models and 166 of which are mouse models. To create models of AD, 24 genes have 
been modified. These genes, along with summaries of the genetic modification of that gene, the 
number of models in which that gene is modified, and references for those models are summarized 
in Table 1. One hundred and thirteen AD models are single gene mutations and 52 are multi-gene 
mutations. One model, SAM-P8, generated through sister-brother mating is used as a model of 
sporadic AD [243]. Of the 24 genes modified in AD, 12 of the targeted genes are within the APP 
pathway and one is within the tau pathway with the remaining genes being associated across 





Table 2: Genetic Modification in Models of Alzheimer's Disease 
Gene Most common modification 
Number of 
Models Reference 




APLP2 KO 1 [244] 
APOE Humanized knock in, 
humanized mutations 
30 [245-252] 
APP Humanized mutations 
(Swedish, Florida, London) 
75 [103, 253-259] 
BACE1 KO 9 [260] 
BACE2 KO 1 [261] 
CEACAM1 KO 1 https://www.jax.org/strain/030673 
CLASP2 knock-in L163P mutation 1 https://www.jax.org/strain/031944 
CR1 Humanized 1 https://www.jax.org/strain/031668 
CR2 Humanized 1 https://www.jax.org/strain/031668 
1L1RAP KO 1 https://www.jax.org/strain/030304 
ITM2B Humanized mutation 2 [262, 263] 
KIF21B knock-in T82T mutation  1 https://www.jax.org/strain/031938 
MAPT Humanized knock in, 
Humanized mutations 
(P30IL, P301S, A152T, 
L266V, G272V, R406W)  
29 [103, 264-290] 
MTHFR A262V Knock in 1 https://www.jax.org/strain/030922 
NOS2 KO 1 [291, 292] 
PDGFRB KO 1 [293] 
PLCG2 KO, M28L knock in 2 https://www.jax.org/strain/030674 
https://www.jax.org/strain/029910 
PSEN1 Knock in (PS1M146V,  
Humanized mutation (R278I, 
M233T, L235P, L166P), 
humanized knock in 
38 [103, 250, 253, 255, 271, 294-
300] 
PSEN2 Humanized, KO, Humanized 
mutation (N141I) 
7 [282, 301-303] 
RAGE Humanized, Truncation 
mutation 
2 [304] 
SNX1 D465N mutation 1 https://www.jax.org/strain/031942 
SORL1 A528T mutation 1 https://www.jax.org/strain/031940 
TREM2 Loss of function mutation 
(R47H) 




 Genetic models of AD face criticism of their poor predictive validity, construct validity, 
and induction validity. These concerns have a valid basis. Thousands of compounds have been 
tested in many of the models described here with great effect, but have failed to pass clinical trials, 
indicating a failure of predictive validity. Given the low number of AD cases caused by genetic 
mutation [1], the use of genetic mutation to construct and induce these models is a clear concern. 
Despite these concerns, there are currently very few alternatives. 
 One alternative to genetic modeling is the use of Aβ injection into the brain. Researchers 
have successfully created models via intracerebroventricular injection [311, 312] or bilateral 
dorsal hippocampus injections [313, 314] of Aβ oligomers. While these models avoid the 
developmental and genetic validity problems associated with genetic models, they do not solve 
the induction criteria. Further, the stress of daily brain injections, as is done in these models, creates 
an additional factor that must be accounted for in model development. Additionally, brain 
injections risk brain damage that could obscure or bias results. 
 Intravenous injection of Aβ oligomers avoids the problems of direct brain injections and 
showed efficacy in a 2018 study [315]. However, daily injections still create stress and still do not 
accurately model the induction or construct validity. 
 Because the effects of CypD in reducing Aβ-induced AD pathology are well characterized, 
we chose to study tau models. Tau pathology poses an interesting target in AD study due to the 
high correlation between HFT deposits and cognitive decline. For these studies, tau models 
without amyloid gene mutation were chosen in order isolate effects of tau separate from any effects 
of Aβ. Aβ and tau have interactions that can confound the determination of pathways [316]. 19 
models that fit these criteria were identified and are compared in Table 2 based on the age at which 
AD-like symptoms appear. A dash “-“ marks criteria that have not been experimentally tested, 
while negative data appears is labeled “nd”. Negative data, in this context, indicates pathology that 
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was tested and found to be absent; for example, models in which synaptic loss was tested but not 
identified. While not all models generate neurofibrillary tangles, also known as tau tangles, all 
models show hyperphosphorylated tau and other abnormal tau pathologies. mitochondrial 


















hTau-A152T - 20 mo - nd - 10 mo [266] 
hTau-AT 3 mo 12 mo 10 mo 10-16 mo - 16 mo [267] 
hTau.P301S 4 mo 3 mo nd 5-6 mo nd 2.5 mo [268] 
JNPL3(P301L) 4.5 mo 10 mo 10 mo nd nd nd [269] 
mThy-1 3R Tau 8 mo 8 mo 8 mo nd nd 6-10 mo [270] 
rTgTauEC 18 mo 24 mo 24 mo 24 mo 16 mo 16 mo [272] 
rTg(tauP301L)4510 2.5 mo 5.5 mo nd 8 mo 4.5 mo 2.5 mo [317] 
Tau35 14 mo nd - 14 mo nd 8 mo [275] 
Tau4RTg2652 - - nd nd nd 3 mo [276] 
Tau609  15 mo 15 mo 12 mo 6 mo 6 mo 6 mo [274] 
TauC3 - - - 1.3 mo nd 1.3 mo [277] 
TauΔK280 24 mo - nd 13 mo nd nd [279] 
Tau P301L 8 mo nd 7 mo 1-2 mo 6 mo 5 mo [280] 
Tau P301S* 6 mo 12 mo 3 mo 3 mo 6 mo 6 mo [281] 
Tau R406W 18 mo nd nd nd nd 16 mo [283] 
TauRDΔK280 2 mo 5 mo 21 mo 9.5 mo 10 mo 10 mo [284] 
Tau V337M 11 mo 10 mo nd nd - 11 mo [318] 
THY-Tau22 3-6 mo 12 mo - nd 10 mo 9 mo [287] 
TMHT 4 mo nd nd nd nd 5 mo [288] 
 
 For this study, the Tau P301S line, also referred to as PS19 mice, was chosen due to the 
high level of characterization of the model, the timely development of tangles and neuronal loss, 
and the established memory deficits [281]. Models that developed severe tangle pathology within 
2-3 months, like the TauRDΔK280 mice, were avoided due to their particularly poor induction 
validity [284]; with AD as an aging disease, it was important that the model chosen for these 
studies be tested in an aging condition. Mice that developed only partial pathology, like the TauC3 
mice, were avoided in order to focus on a model that recapitulated the AD-like pathology that 
these studies would address [277]. Finally, models that developed symptomology after only very 
late time points, like the rTgTauEC model, were avoided in order to streamline research objectives 
[272]. 




Statement of Purpose 
 This dissertation will explore the mechanistic links by which aging and tau pathology 
contribute to mitochondrial dysfunction and cognitive impairments, as well as the therapeutic 
possibilities of targeting CypD in Alzheimer’s disease. These studies will explore hitherto 
unknown roles for CypD in aging animals and propose possible therapeutic options for age-
induced cognitive failure. Further, this study will build on previous work linking CypD and mPTP 
opening to Aβ by demonstrating a causal link between HPT and CypD triggering mitochondrial 




Schematic 1: Dissertation hypothesis of the role of CypD in aging and AD 
Aging initiates an opening of the mPTP via CypD triggering mitochondrial failure, which leads to 
synaptic loss and cognitive impairment. Hyperphosphorylated tau filaments provoke the CypD-
mediated opening of the mPTP via GSK3β signaling which leads to mitochondrial failure, synaptic 






Open field was conducted using a force plate actometer developed as described [319, 320]. 
Briefly, the apparatus consists of a 30 cm by 30 cm box with acrylic walls and lid. Four force 
transducers operating at 200 samples per second collect force data that is then processed. Mice 
were acclimated to the procedure room for 30 minutes prior to the experiment beginning. Mice 
were placed in the apparatus and left alone for the 30-minute test. Locomotion was based on total 
movement throughout the apparatus. Anxiety was measured by determining time spent in the 
center of the arena [321, 322]. The center was defined by dividing the arena into two zones, center 
and outer, of equal area. 
Body weight 
Body weight measurements were made using the force plate actometer. Mass was 







Analysis of force actometer data  
Force data is processed in Matlab following Fowler et al. (2001) in that the force data is 
analyzed for “center of force” following equation 1: 
𝑋𝑐 =
(𝑥1𝑓1 + 𝑥2𝑓2 + 𝑥3𝑓3 + 𝑥4𝑓4)
(𝑓1 + 𝑓2 + 𝑓3 + 𝑓4)
 
 Where Xc is the location in the x coordinate of the mouse at the given time. The same is 
performed for the y Cartesian coordinate. This provides location data at a rate of 200 samples per 
second. However, this high volume of data includes a significant portion of noise from locomotive 
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movements of the mouse that do not affect the mouse’s location. To resolve this, a two-stage 
process was used to eliminate noise in the data and to provide a more accurate estimate of location 
and distance travelled. First, location data is analyzed for erroneous data, defined as location data 
that locates the mouse outside of the box. These points are eliminated by replacing the value with 
the value of the previous data point. Data is replaced with the value of the previous data point to 
maintain the time location of each data point following the erroneous value. Once the data is 
processed for erroneous values, it is smoothed by a moving average that is 100 samples long, 
eliminating much of the vibrational noise of the system. This averaging method has no ill effects 
on mouse location, but it does reduce the overall length of the analyzed data stream by a total of 
100 samples (0.5 seconds) because the first average cannot be performed until there are 50 samples 
and the last average can only be performed until there are 50 samples remaining. A 100-sample 
moving average was chosen to reduce the effects of individual values while still maintaining a 
high enough sampling rate to accurately locate the mouse center of force.  
 Total distance is calculated between smoothed location points by summing the distance 
between points as follows: 
𝐷𝑖 = √(𝑥𝑖 − 𝑥𝑖+1)2 + (𝑦𝑖 − 𝑦𝑖+1)2 
 Where Di is the distance between point i and i+1, xi/yi is the initial location, and xi+1/yi+1 
is the next location. 
 Time in center is calculated by summing the total number of points within the inside box 
(5 cm away from the edge) and comparing it with the number of points in the outside box (within 
5 cm from the edge). 
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Nesting experiment  
Nesting was performed according to the protocol found in [323]. Briefly, mice were given 
3 g of compressed cotton nestlet. In group housing, mice were given a new nestlet 2 hours before 
the dark cycle for 4 subsequent days. On the fifth day, mice were individually housed with a new 
nestlet and allowed to build a nest. Nests were scored 16 hours later on a scale of 1 to 5 based on 
published protocols and described in Table 4 [324]. Untorn nestlets were additionally weighed for 
further analysis. 
Table 4: Nest Scoring Protocol 
Score Explanation 
1 Less than 10% of nestlet torn 
2 10-90% of nestlet torn 
No nest assembly 
3 More than 90% of nestlet torn 
No nest assembly 
4 More than 90% of nestlet torn 
Nest assembled into less than 25% of cage area 
No vertical assembly of nest 
5 More than 90% of nestlet torn 
Nest assembled into less than 25% of cage area 
Vertical assembly of nest, would cover mouse 
 
Mice maintenance  
All animals were housed under pathogen-free conditions according to AAALAC 
guidelines. All animal-related experiments were performed in full compliance with institutional 
guidelines and approved by the Animal Care and Use Committee of the University of Kansas. 
Two-month-old SCID mice were purchased from Jackson Laboratories and continuously bred on 





 Amplex Red Hydrogen Peroxide/Peroxidase Assay Kit (Cat#A22188; Invitrogen) was 
used according to the manufacturer’s instructions with 10 µG of protein. In short, Amplex Red is 
combined with horseradish peroxidase to detect H2O2 released from cells. Amplex Red reacts 1:1 
with H2O2 to produce resorufin. Resorufin as an excitation/emission ratio of 571nm/585nm, which 
allows the amount of H2O2 to be measured via spectrophotometer. 
Mitochondrial Electron Transport Chain Complex Activity 
Complex I and IV were measured via spectrophotometer. A working solution of 25 mM K 
buffer and an Ultrospec 3100 pro spectrophotometer were used for both assays. Complex assays 
were expressed as nanomoles of substrate oxidized per mg-1 protein min-1 ml-1 (nmol/mg 
protein/min/ml) converted to fold increase. 
Complex I 
Cortical tissue lysates (30-50 µG of protein/ml) and 0.5 ml of Complex I reaction buffer were 
added to a 2 mL cuvette. 2 µL of 65 µM Coenzyme Q1 begins the reaction and 2 uL of 2 µG/mL 
rotenone is added at 180 seconds. Oxidation of NADH causes a decrease in absorbance at 340 nm 
which can be measured in 20 second intervals over 18 readings. 
Complex IV 
Cortical tissue lysates (30-50 µG of protein/mL) and 0.475 mL of assay buffer were added 
to a cuvette. A dilution buffer was used to bring the total volume to 0.525 mL 25 µL of 0.22 mM 
ferrocytochrome c solution is added for incubation. Oxidation of cytochrome c causes a change in 






Continuous polyacrylamide-gel electrophoresis (SDS-PAGE) was used to measure protein 
from brain tissue. Protein extracts at 2-5 μg/μL were boiled with 1 X SDS sample buffer for 5 min 
at 100°C. Samples were separated on a 12% separating gel topped with 4% stacking gel with a 
visible protein molecular weight standard. Gels were run at 80 V through the stacking gel and then 
100 V until the samples reached the bottom of the gel. A 12% separating gel topped with 4% 
stacking gel was prepared as follows for a standard size SDS gel: 
Table 5: Composition of SDS-PAGE gels 
Material 1 separating gel 1 stacking gel 
H2O (RT) 2.1 ml 1.0 ml 
30% bis-acrylamide (4°C) 1.8 ml 220 μl 
Separating buffer (4°C) 560 μl ---- 
Stacking buffer 4°C) ---- 440 μl 
10% SDS (RT) 45 μl 18 μl 
15% APS (4°C) 23 μl 9 μl 
TEMED (4°C) 3 μl 2 μl 
 
After SDS-PAGE, proteins were transferred to a 0.45 μm nitrocellulose membrane 
(Thermo Fisher Scientific) by wet transfer at constant voltage at 110 V for 80 minutes on ice in 
Western blot transfer buffer. The membrane was incubated in 5% milk buffer in tris-buffered 
saline (TBS) for 30 minutes at room temperature to block non-specific binding. Primary antibodies 
were incubated overnight at 4°C. The membranes were washed 3 times for 15 minutes using TBS 
at room temperature. The membranes were incubated with secondary antibodies for 1-4 hours at 
room temperature. Membranes were washed 3 times for 15 minutes at room temperature.  
Specific protein bands were visualized by chemiluminescence using Super Signal West 
Pico Chemiluminescent Substrate and a FluorChem HD2 image system. Table 6 contains 
information specific to particular antibodies used in this study. 
34 
 
Table 6: Antibodies used for protein quantification 
Protein of Interest Antibody Source Concentration Secondary Secondary 
incubation 
time 
HPT AT8  1:500  2 hours 
CypD   1:2000 Mouse 1 hour 
Synaptophysin   1:1000 Mouse 1 hour 
Neuronal tubulin   1:2000 Mouse 1 hour 
pAKT   1:1000  2 hours 
tAKT   1:1000  1 hour 
p(ser9)GSK3β   1:500  2 hours 
p(tyr216)GSK3β   1:500  2 hours 
tGSK3β   1:1000  1 hour 
 
TMRM staining 
 Brain tissue was incubated with 150 nM Mito Tracker Green and 100 nM TMRM for 30 
min followed and then washed twice with HBSS media. Tissue was imaged by confocal 
microscopy and the intensity of fluorescence was recorded to determine the uncollapsed proton 
gradient. 
ATP Assay 
ATP levels were measured using the Bioluminescence Assay Kit HS II. following the 
manufacturer’s instructions as previously described. Tissue was sonicated using 50 µL lysis buffer. 
Protein content was determined using the BCA assay. 25 µL of sample and 25 µL/well ATP 
Dilution Buffer were added to a 96 well plate. ATP levels were determined using an LMax II 384 
Microplate Reader and SoftMax Pro. 
CypD Staining 
Brains were sectioned and stained with goat anti-CypD and anti-goat antibody 
conjugated with rhodamine diluted 1:1000. Sections were incubated in Sudan black at 1:100 to 
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block autofluorescence. Neurotrace 640 was incubated at 1:150 in order to visualize nuclie. 
Images were taken using confocal microscopy. 
 Statistical analysis  
All statistics were performed using StatView. Comparisons between more than two groups 
were performed using a one-way ANOVA with Tukey’s post hoc test. Sex comparisons were 
performed using Student’s t-test. Motion patterns and binding assays were analyzed using 





Chapter 2 : The role of CypD in Aging Mice 
 Wild type C57/BL6 mice were used to assess behavioral and biochemical changes in mice 
as they aged from three months of age to 24 months of age. Complementarily, CypD 
overexpression (OE) and KO mice were used to determine the role of CypD in this process. 
Two behavioral tests were employed. Open field was used to measure gross motor 
function, patterns of motion, and body weight to measure metrics of health and determine that 
mice were fit for further testing. Nesting activity was used to assay daily task performance, a 
sensitive metric of learning and memory that combines long term memory with working memory.  
Biochemically, ROS, mitochondrial function, and proteins of interest were measured. ROS 
was measured via a H2O2 assay. Mitochondrial function was measured using a spectrophotometer-
based colorimetric assay. Proteins of interest were measured using western blotting. These 
techniques are described in detail in the methods section. 
Aging mice used in the experiments described in 2.1-2.4 are not the same as the cohorts 
used in experiments described in 2.6-2.12.  
This chapter tests the sub-hypothesis presented in Schematic 2. We hypothesize with 
increased age, there is increased mPTP opening. This leads to mitochondrial failure, and the 
subsequent energy loss causes synaptic loss and cognitive impairment. 
 




2.1 Gross locomotion, patterns of motion, and body weight 
 First, novel open field was used to assess total distance traveled in a 30-minute period. 
Between ages, there were no significant changes in the total distance traveled (p=0.83) (Fig. 2-1 
A). Males and females were analyzed separately, and no significant differences were observed 
(p=0.14, p=0.11) (Fig. 2-1 B-C). Distance traveled in five-minute increments was then assessed to 
determine whether patterns of exploration and rest were different with age. When analyzed for sex 
and age, no significant differences were seen (p=.21) (Fig. 2-1 D). 
 Finally, we used force plate measurements to assess changes in body weight with age. This 
was done as a metric of health in animals as they age, as there are well-established parameters for 
patterns of healthy weight gain in mice, as identified by Jackson Laboratories. These mice 
maintained healthy body weights throughout the duration of this experiment (Fig 2-1 E). This data 





Figure 2-1: Male and female mice maintain similar patterns and levels of general locomotion 
Total distance traveled does not change from 3 to 20 months. When analyzed by sex, there is no 
significant difference in male or females for total distance traveled at any age. When analyzed in 
five-minute increments, there is no significant change in locomotion patterns based on either sex 
or age. As animals aged from 3 to 20 months, they maintained healthy body weight conditions.  
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2.2 Anxiety-like behaviors in aging mice 
Anxiety-like behaviors were measured via time spent in the center of a novel open field 
apparatus. As mice are naturally explorative animals, open field exploration gives a reliable and 
more physiological assessment of anxiety than other common tests [322]. When assessed with 
male and female mice combined, there was a significant decrease of time in the center of the arena 
in both 12- and 24-month-old mice (p=.006) (Fig. 2-2 A/B). Male mice aged 12 and 24 months 
did not show a significant decrease in time in the center (p=0.83) (Fig. 2-2 C). However, female 
mice showed significant decreases in time spent in the center at 12 months and 24 months 
(p=0.001) (Fig. 2-2 D). 
To determine whether the different times spent in the center was because of different 
motion patterns, we assessed time spent in the center in five-minute increments. Linear regression 
of this data revealed that while the intercepts were significantly different (p=0.005), indicating 
differences in time, the slopes were not significantly different (p=0.27) (Fig. 2-2 A). This indicates 




Figure 2-2: Anxiety-like behavior in aging mice 
Mice show reduced time spent in the center of the arena. Males, analyzed alone, do not show any 
decrease in time spent in the center of the arena. Females, analyzed alone, show a significant 
decrease in time spent in the center of the arena. There is no significant change in exploration 
patterns in either males or females as they age.   
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2.3 Daily task performance in aging mice 
 The nesting paradigm assesses daily task performance based on the quality of a nest built 
by an individual mouse. Young, 3-month-old mice build nearly perfect nests. By 12 months of 
age, the nests are less proficiently built (p=0.001). From 12 months to 24 months, mice trend 
towards significantly worse nest building (p=0.12) (Fig. 2-2 A). Due to significant sex differences 
in the open field paradigm, sex differences in nest building were analyzed. There were no 
significant differences between male and female mice at any age point (p=0.50, p=0.31, p=0.20) 
(Fig. 2-2 B-D). Untorn nesting material was recorded by weight (Fig. 2-2 D). No 3-month-old 
mouse failed to completely tear up their nestlet, compared with two 12-month-old mice (6.25%) 
and seventeen 24-month-old mice (70.83%). The increase in nestlet left untorn was statistically 





Figure 2-2: Daily task performance in aging mice 
Nesting activity decreases with age. Nesting activity is not sex-dependent, and the decrease seen 
with age is not sex dependent. Untorn nestlet weight increases with age, with a significant increase 
occurring at 24 months. * p < 0.05 vs 3 months, ** p < 0.01 vs 3 months, *** p < 0.001 vs 3 
months ### p < 0.001 vs 12 months.  
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2.5 ROS in Aging Mice 
 An H2O2 assay was utilized to measure ROS in cortical brain tissue from C57/Bl6 mice 
(Fig. 2-3). When compared to 3-month-old mice, the 12-month and 24-month-old mice have 
significantly more ROS (p < 0.05, p < 0.01). From 12 months to 24 months, mice showed a trend 
towards further increasing of ROS (p = 0.057). ROS was not analyzed based on sex differences, 
but included mixed sex groups with no trend towards differences. 
H2O2 Levels


























Figure 2-3: Reactive oxygen species in aging mice 
Reactive oxygen species increase in aging mice at both 12 and 24 months. * p < 0.05 3 months vs 
12 months, ** p < 0.013 months vs 24 months.  
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2.6 Mitochondrial function in Aging mice 
 The electron transport chain is composed of four complexes, named Complex I-IV, and the 
ATP synthase complex, sometimes called Complex V. Complex I and IV are measured here due 
to their importance in this chain. Complex I is the initial step in the ETC and also the largest 
producer of ROS. Complex IV is the rate limiting step in the ETC. 
 When compared to 3-month-old mice, 12-month- (p < 0.001) and 24-month-old mice (p < 
0.001) showed significantly lower levels of Complex I activity. 24-month-old mice showed a 
significant decrease in Complex I activity when compared to 12-month-old mice (p < 0.01) (Fig. 
2-4 A). 
 12-month-old mice showed significantly reduced Complex IV activity compared to 3-
month-old mice (p < 0.001). 24-month-old mice showed significantly reduced Complex IV 
activity compared to 3-month-old mice (p < 0.001) and 12-month-old mice (p < 0.01) (Fig. 2-4 
B). 
 
Figure 2-4: Mitochondrial complex activity in aging mice 
Mitochondrial function, as measured by electron transport chain activity, decreases steadily with 
age. By 24 months, complex I activity has decreased by nearly 50%. ** p < 0.01 vs 3 months, *** 
p < 0.001 vs 3 months, ## p < 0.01 vs 12 months 
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2.7 CypD expression in aging mice 
Our laboratory used antibody-based immunohistochemistry to test expression levels of 
CypD at 3 and 12 months. While CypD expression was not tested in 24 month, there is a 
significant increase in CypD levels from 3 to 12 months (p < 0.01) (Fig. 2-5). 
 
Figure 2-5: CypD Expression in Aging Mice 




2.8 Gross motor function and weight 
 Due to the increased expression of CypD identified in aging mice, we looked at genetically 
modified CypD mice: CypD OE and CypD KO. To parallel experiments done in the wild type 
mice in sections 2.1-2.3, mice were studied at 3-months, 12 months, and 24 months and observed 
on several behavioral parameters. However, CypD OE mice were only studied at 3 months and 12 
months because these mice have an average life expectancy of less than 15 months.  
 Previous studies have identified that wild type mice do not show changes in gross motor 
function from 3 months to 24 months [325]. Modification of CypD through overexpression or 
knock out does not cause changes in gross motor function (Fig. 1 A-C), indicating that these mice 
are healthy and capable of performing behavioral tests. 
 
Figure 2-6: Gross locomotion in CypD modified mice 
Gross locomotion is not affected by CypD overexpression or knockout at any age. n = 6-15  
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2.9 Anxiety like behavior 
At 3 months, CypD modification does not induce an anxiety-like phenotype (Figure 2-7 
A). By 12 months, CypD overexpression mice show significant depression of time spent in the 
center (p < 0.01), indicating a significant anxiety-like phenotype. CypD knock out mice, however, 
do not show a decrease of time in the center compared to wild type mice (Figure 2.7 B). At 24 
months, wild type mice show a significant increase in anxiety-like behavior [325], which is 
recapitulated here. CypD knock out mice show no such decrease (Figure 2.7 C).  
Surprisingly, 24-month CypD knock out mice do not show the age-induced depression in 
time in center (p = 0.119 3-month wild type vs 24-month CypD knock out). These results indicate 
that while CypD expression influences anxiety like behavior, with overexpression resulting in 
anxiety-like behavior earlier and CypD knock out preventing the age-dependent phenotype.  
CypD OE and CypD KO mice do not show sex dependent effects at any age point, in 
contrast to wild type mice which show the same variation presented in earlier figures. 
 
 
Figure 2-7: Anxiety like behavior in CypD Modified mice 
At 3 months, there anxiety-like behavior is not affected by CypD expression status. At 12 months, 
CypD KO mice show significant reductions of time in the center, while CypD KO mice remain 
unchanged. At 24 months, CypD KO mice do not show anxiety like behavior while wild type mice 






2.10 Daily Task Performance 
 Daily task performance is an assay of memory that combines both long term memory and 
working memory [324]. Nest building in mice is a natural behavior done for thermoregulation that 
the mice learn as pups [326]. Previous studies have identified that mice fail in this assay of daily 
task performance as they age [325]. At 3 months, mice build nests that score between a 4 and 5 
regardless of genotype (Fig. 2.9 A), indicating proficiency at nest building; CypD overexpressing 
mice built nests that were statistically (p < 0.05) better than their wild type counterparts, a nesting 
score of 4-5 is considered healthy and normal [323, 324]. 12-month old CypD overexpressing mice 
display significantly diminished nesting activity (p < 0.01) compared to wild type mice (Fig. 2.9 
B). CypD knockout mice, however, maintain their high level of proficiency in task performance. 
24-month wild type mice show impaired nest building activity, in line with previously published 
work [325]. At this time point, CypD knock out mice do not display the same loss of function (p 
< 0.001) and still build excellent nests (Fig. 2.9 C). These data indicate that CypD overexpression 
exacerbates age-induced daily task performance failure, while CypD knock out ameliorates them.  
 
Figure 2-8: Daily task performance in CypD modified mice 
CypD KO improves nesting scores at all age points. At 12 months, CypD OE causes significant 
depression in nesting activity. * p < 0.05 wild type vs CypD-, ** p < 0.01 wild type vs CypD+, 
*** p < 0.001 wild type vs CypD+ 
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2.11 ROS in CypD KO Aging mice 
 ROS were measured in 20-month-old CypD KO mice and 20-month-old wild type mice in 
both the cortex and hippocampus [23]. Brain tissue was stained using MitoSox, which targets the 
mitochondria and fluoresces upon interaction with superoxide, allowing the measurement of ROS 
specifically produced by the mitochondria. 
 CypD KO mice showed significantly reduced MitoSox staining, indicating a significant 
reduction of ROS (Figure 2.10). 
 
Figure 2-9: CypD KO mice show less ROS in cortex and hippocampus 





2.12 Mitochondrial activity in aging CypD KO mice 
 Mitochondrial membrane polarization was measured via TMRM staining, which is isolated 
in highly polarized membrane compartments. If the mPTP opens and the mitochondrial membrane 
polarity gradient is lost, TMRM staining is decreased. 
 Mitochondrial swelling is measured via optical density. When the mPTP opens, 
mitochondria swell. This is usually initiated via a calcium bath of cells or tissue, which induce 
mPTP opening. 
 Calcium buffering capacity is measured with a calcium sensitive probe. As calcium is 
added, mitochondria sequester the calcium in the matrix. However, mitochondria do not have 
limitless buffering capacity, and the mPTP will open at some point in the experiment, resulting in 
a lack of uptake of the next calcium input. 
 Wild type and CypD KO mice were used to measured mitochondrial membrane 
polarization with addition of H2O2. H2O2 causes damage to mitochondria which can be seen in the 
decrease in TMRM staining. Brain tissue from wild type mice showed significant decreases in 
mitochondrial membrane polarization with increasing doses of H2O2. CypD KO mice did not show 
a significant decrease in mitochondrial membrane polarization (Figure 2.11 A). This can be 
interpreted as CypD KO mice being more resistant to ROS-insult. 
  Mitochondrial swelling was reliably induced by Ca2+ in wild type mice (Figure 2.11 B). 
However, calcium did not induce mitochondrial swelling in CypD KO mice. CypD KO mice with 
calcium addition did not significantly differ from CypD KO mice with vehicle addition or wild 
type mice with vehicle addition. 
 Calcium buffering capacity was tested in wild type mice and CypD KO mice. CsA was 
used in wild type mice to serve as positive control for CypD inhibition (Figure 2.11 C). In both 
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the CsA treated wild type mice and the CypD KO mice, calcium buffering capacity was 
significantly increased when compared to wild type mice. 
 
 
Figure 2-10: Mitochondrial function in CypD modified mice 
A. Hydrogen peroxide induced membrane depolarization is increased by CypD KO. B. 
Mitochondrial swelling induced by calcium is reduced. WT + vehicle vs Wt + Ca2+ p < 0.01 , WT 
+ vehicle vs CypD KO + Ca2+ n.s. C. Calcium buffering capacity is increased by CypD KO. * p < 





Chapter 2 Interim conclusion 
 As mice age from 3 to 24 months, significant cognitive declines were identified. Anxiety-
like behaviors were evident in 12- and 24-month female mice that had not been previously 
identified (Figure 2.2). Additionally, failures in memory and daily task performance were 
identified in a nesting assay (Figure 2.3), were identified in a nesting assay. We hypothesize that 
these cognitive failures are the result of mitochondrial failure, both in complex I and IV activity 
(Figure 2.5) and in increased ROS production (Figure 2.4). 
 We hypothesized that inhibition of CypD could prevent these cognitive impairments. We 
used CypD OE and KO mice to assess the role of CypD in aging-induced cognitive impairments.  
CypD OE induced cognitive impairments at an earlier age than in wild type mice. CypD 
OE also showed more pronounced anxiety-like behavior at six months (Figure 2.7) and impaired 
nesting behavior at 12 months (Figure 2.8). CypD OE mice prematurely died at around 15 months 
while wild type and CypD KO mice lived beyond 24 months with their general physical health 
intact (Figure 2.6). 
CypD KO mice did not show impaired cognitive function, even at 24 months (Figure 2.7-
2.8) when wild type mice were showing anxiety-like behavior and decreased memory and daily 
task performance, confirming a role for CypD in cognitive impairment. 
CypD OE mice were not studied in molecular tests due to the results of the behavioral 
experiments; because there was a clear degenerative phenotype, we chose to focus on the genetic 
modifications that represented a potential therapeutic intervention. CypD KO prevented 
mitochondrial dysfunction as assessed by ROS production (Figure 2.10), membrane potential 
maintenance (Figure 2.11 A), and calcium buffering capacity (Figure 2.11 B-C). 
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Taken together, these studies support the hypothesis that elevated CypD expression 
modulated mitochondrial function which results in cognitive impairments through the course of 




Chapter 3 : The Role of CypD in Alzheimer’s disease Mice 
 In order to study the role of CypD in a tau model of Alzheimer’s disease, several animal 
lines were developed. First, CypD OE were crossed with the P301S tau mice to create a line of 
double transgenic CypD OE/Tau+ mice. Cypd OE/Tau+ mice were intended to simulate the 
elevated levels of CypD seen in AD and to assess the role of CypD in tau-induced AD.  
 To assess the potential therapeutic role of reducing CypD activity, CypD KO mice were 
crossed with the P301S mice to generate a line of CypD KO/Tau- mice. 
Six genotypes of mice were used for these experiments and are summarized in Table 6. 
Table 7: Mouse lines used in Chapter 3 
Genotype Mouse Line Origin 
Wild type C57/Bl6 Bred internally 
Tau+ P301S Tau OE [281] 
CypD OE CP11 Created internally 
CypD KO BE [327] 
CypD OE/Tau+ Crossed CypD OE / P301S 
Tau OE 
Created internally 
CypD KO/Tau+ Crossed CypD KO / P301S 
Tau OE 
Created internally 
Experiments for this chapter were divided into two sub-sections based on the type of CypD 
manipulation: 
1. Wild Type, Tau+, CypD OE, and CypD OE/Tau+ 
2. Wild Type, Tau+, CypD KO, and CypD KO/Tau+ 
Unique wild type and Tau+ mice were used for the two sub-sections of experiments.  
CypD and HPT levels were assessed via western blot. In line with the hypothesis laid out 
in Schematic 1, mitochondrial failure was assessed with by assaying ETC complex activity. 
Synaptic and neuronal loss were measured by western blots of synaptophysin and neuronal tubulin. 
Cognitive levels were measured with two behavioral tests. The open field test was employed to 
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measure anxiety-like behavior and nesting was used to measure learning and memory in a daily 
task performance test. 
The experiments in this chapter test the two sub-hypothesis presented in Schematic 3. 
Namely, that overexpression of tau, resulting in higher levels of phosphorylated tau will lead to 
CypD opening the mPTP. The open mPTP will induce mitochondrial failure and the resulting 
energy losses will cause synaptic loss. Finally, the summation of these molecular events will be 
cognitive impairment. Conversely, knock out of CypD will prevent mitochondrial dysfunction and 
the synaptic loss and cognitive impairment that hypometabolism causes. 
 




3.1 CypD expression in tau-models of Alzheimer’s disease with CypD overexpression 
 CypD OE mice have shortened lifespans (~15 months), as noted in Chapter 2, and this was 
heightened in CypD OE/Tau+ mice, which survived regularly to 10-12 months. At the 12-month 
time point, survivor bias made them unsuitable for inclusion in these experiments. 
 Western blots at 3 months were performed with 15 µG of protein. At 3 months, there is 
already significantly heightened expression of CypD in the CypD OE/Tau+ mice compared to the 
CypD OE mice alone (p < 0.001). While there was CypD detectible in wild type mice and Tau+ 
mice, it was far eclipsed by the genetically modified CypD OE models at 3 months (Fig. 3.1A). 
 Western blots at 6 months were performed with 5 µG of proteins. The amount of protein 
used for these experiments was determined experimentally for each age group; less protein was 
used in older mice due to the accumulation of tau that made discerning differences in expression 
impossible. At 6 months, there was a ceiling effect in which CypD OE and CypD OE/Tau+ mice 
showed similar levels of CypD expression, although both were significantly elevated when 
compared to wild type mice (p < 0.01). At 6 months, Tau+ mice showed significant increases in 





Figure 3-1: Validating CypD Expression in CypD OE/Tau+ mice 
Data is presented as CypD expression normalized to actin expression in relative units. CypD OE 
mice have higher levels of CypD expression than Wild type or Tau+ mice at 3 and 6 months. *** 





3.2 Hyperphosphorylated tau models of Alzheimer’s disease with CypD overexpression  
 HPT was measured to assess changes in HPT accumulation based on CypD expression. At 
three months, 15 µG of protein was used, while at six months only 5 µG of protein was used; this 
change was done based on experiments optimizing the best protein amount for respective ages. 
With too much protein, particularly in these HPT westerns, there was a higher risk for 
overexposure from non-specific protein bands that appeared to overlap with tau. 
 At three months, Tau+ mice showed elevated levels of HPT compared to wild type mice 
(p < 0.01). CypD OE/Tau+ mice showed elevated HPT levels when compared to wild type mice 
(p < 0.001) and when compared to Tau+ mice (p < 0.01) Fig. 3.2A 
. 
 At six months of age, Tau+ mice maintained their high levels of HPT compared to wild 
type mice (p < 0.01). CypD OE/Tau+ mice showed an even greater increase in HPT that was 





Figure 3-2: Validation of Phosphorylated tau in CypD OE/Tau+ mice 
Data is presented as phosphorylated tau normalized to actin and then normalized to wild type 
levels. Phosphorylated tau is increased in Tau+ and CypD OE/Tau+ mice at 3 and 6 months. n = 
4-7 * p <0.05 Wild type vs Tau+, ** p < 0.01 wild type vs. Tau+, *** p < 0.001 wild type vs 




3.3 Synaptic loss in a tau-induced model of Alzheimer’s disease with CypD overexpression 
 Synaptophysin was analyzed to assess synaptic loss. As with the previous experiments, 
two conditions were used for the respective age points. 15 µG of protein was used for three month 
mice and 5 µG of protein was used for six month mice. 
 At three months, there are no significant changes in synaptic loss despite the significant 
HPT accumulations identified in Figure 3.2. This may indicate that the three month time point 
represents an intermediate stage between pathologically accumulated protein and irreversible 
neuronal damage. Fig. 3.3A 
 At six months, there is a significant decrease in synaptophysin staining for Tau+ mice (p < 
0.05) and a decrease in the CypD OE/Tau+ mice. There was a non-significant trend towards CypD 
OE/Tau+ mice having less synaptophysin expression when compared to Tau+ mice. While a later 
time point may have helped to clarify this, the early mortality of the CypD OE/Tau+ mice made 




Figure 3-3: Synaptophysin in CypD modified AD mice 
At 6 months, synaptophysin is reduced in Tau+ and CypD+/Tau+ mice compared to wild type 
mice. n = 4 * p < 0.05 wild type vs Tau+, ** p < 0.01 wild type vs CypD+/Tau+  
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3.4 Neuronal loss in tau-induced models of Alzheimer’s disease with CypD overexpression 
 Neuronal loss was assessed with western blots for neuronal β-tubulin. As with previous 
studies, 15 µG of protein was used for the three month time point while 5 µG of protein were used 
for the six month time point. 
 Similar to the synaptophysin experiments, at three months there was no significant loss of 
tubulin expression in the Tau+ or CypD OE/Tau+. Surprisingly, there was a significant increase 
in tubulin expression in the Tau+ mice (p < 0.05). Fig. 3.4A 
 At 6 months, paralleling synaptic loss, Tau+ mice showed significant decreases in 
expression of neuronal tubulin (p < 0.05) which was also seen in CypD OE/Tau+ mice. Due to 
floor effects, there was no significant difference in neuronal loss between Tau+ and CypD 
OE/Tau+ mice. Fig. 3.4B 
 
Figure 3-4: Tublin in CypD Modified AD Mice 
Tubulin expression is decreased in Tau+ mice and CypD OE/Tau+ mice at six months. 
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3.5 Mitochondrial electron transport chain activity in tau-induced models of Alzheimer’s disease 
with CypD overexpression 
 Mitochondrial activity was assessed by assays of complex IV activity. Complex IV was 
selected because it is the rate limiting step of the ETC. Mice were studied at the 12-month end 
point for this experiment, and data is presented with the caveat that survivor bias is affecting the 
outcomes; interpretation of the data should be done with that in mind. While differences in protein 
accumulation made it necessary to use different amounts of protein for western blotting, no such 
concern was found in mitochondria studies. 
 Wild type mice, showed decreases in Complex IV function by 12 months. This same 
pattern of decrease at both 6 and 12 months was paralleled in Tau+ mice and CypD OE/Tau+ mice. 
Unexpectedly, CypD OE mice showed preserved mitochondrial function at six months before a 
sharp decline at 12 months. 
 That all mice experienced age-related decline in mitochondrial function made comparisons 





Figure 3-5: Mitochondrial Complex Activity by Genotype in CypD Modified mice 
 At three months, complex IV activity was unaffected by CypD or Tau expression status. At six 





3.7 Gross locomotion in a tau-induced model of Alzheimer’s disease with CypD overexpression 
 Gross locomotion was used to determine the general health and mobility of the animals. 
Animals were assessed at 12 months and that data is presented here with the caveat that it is biased 
by survivorship. CypD OE/Tau+ mice that survived to 12 months were relatively healthy, but were 
the minority of their cohorts, with a majority of mice dying or being humanely euthanized due to 
complications with tau-induced paralysis prior to the 12 month time point. 
 There was no significant change in general locomotion in any genotype. The lack of change 
indicates that further behavioral testing is acceptable and allows for interpretation of this data 
without concern for mobility. 
 
Figure 3-6: General locomotion in CypD Modified AD Mice 




3.8 Anxiety-like behavior in a tau-induced model of Alzheimer’s disease with CypD overexpression 
 Anxiety-like behavior was assessed in these mice to measure cognitive impairments. At 
three months, Tau+ mice already display significant anxiety-like behaviors when compared to wild 
type mice (p < 0.05), with CypD OE/Tau+ mice also showing anxiety-like behaviors (p < 0.01). 
Fig. 3.7A 
 At six months, CypD OE mice (p < 0.05) and Tau+ mice (p < 0.01) show anxiety-like 
behavior which is exacerbated in the CypD OE/Tau+ mice (p < 0.001). CypD OE/Tau+ mice 
showed significantly more anxiety-like effects than the Tau+ mice (p <0.05). Fig. 3.7B 
 
 At 12 months, the data showed significant floor effects with Tau+ mice exhibiting extreme 
anxiety-like behaviors (p < 0.001). CypD OE/Tau+ mice spent nearly no time in the center of the 
arena. Due to the severely depressed time spent in the center, there was no significant difference 
between Tau+ and CypD OE/Tau+ mice, although there was a non-significant trend. The non-
significant trend, paired with the knowledge that the 12-month mice used here represent the 
healthiest and least impaired mice of the cohort, shows that CypD OE/Tau+ are likely more 
impaired than the Tau+ mice. Fig. 3.7C 
 
 
Figure 3-7: Anxiety-like Behavior in CypD Modified AD Mice 
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 At three months, Tau+ and CypD+/Tau+ mice showed significantly decreased time in the center 
of the arena. At six months, CypD+, Tau+, and CypD+ all show decreased time in the center, with 
CypD+/Tau+ mice being significantly less than the Tau+ mice. By twelve months, there is 
significant reduction in time in the center in the Tau+ and CypD+/Tau+ mice. n = 8-10 * p < 0.05 
vs wild type, ** p < 0.01 vs wild type, *** p < 0.005 vs wild type, # p < 0.05 Tau+ vs CypD+/Tau+ 
3.9 Daily task performance in a tau-induced model of Alzheimer’s disease with CypD 
overexpression 
 A nesting assay was used to measure daily task performance and memory. Nesting was 
done after open field to determine that the mice had normal mobility. Additionally, evidence has 
shown that changing housing and nesting materials can affect anxiety-like behaviors [328, 329], 
although not all behaviors are affected. Performing the nesting experiments after open field 
removed any possibility that the measurement of anxiety-like behaviors may be compromised. 
 At three months, Tau+ and CypD OE/Tau+ mice show significant impairment in ability to 
build a nest (p < 0.05). These significant differences were preserved into the 6-month time point 







Figure 3-8: Daily task performance of CypD-modified AD mice 
At 3 and 6 months, Tau+ mice and CypD+/Tau+ mice show significantly reduced nesting activity. 
Representative images show the nestlets built by 6- month-old mice.  
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3.10 CypD and hyperphosphorylated tau expression in a tau-induced model of Alzheimer’s disease 
with CypD knock out 
 CypD expression was measured to assess the quality of the knock out at six months. CypD 
KO and CypD KO/Tau+ mice showed a complete knock out. Fig. 3.9A 
 HPT levels were measured at six months to determine the effect of CypD KO on HPT 
accumulation. While Tau+ mice showed highly elevated HPT levels compared to wild type mice 
(p < 0.001), CypD KO/Tau+ mice showed no such increase. CypD KO/Tau+ mice had 
significantly less HPT than Tau+ mice alone (p < 0.001). Fig. 3.9B 
 
 
Figure 3-9: CypD and Hyperphosphorylated Tau Expression in CypD Modified AD Mice 
Data is presented as phosphorylated tau normalized to actin, normalized to Tau+ levels. Western 
blots reveal that CypD is successfully knocked out in CypD KO and CypD KO/Tau+ mice. 
Phosphorylated tau expression is elevated in Tau+ mice, but normalized in Tau+/CypD KO mice. 




3.11 Synaptic loss in a tau-induced model of Alzheimer’s disease with CypD knock out 
 Synaptophysin was measured at six months to assess synaptic loss. While Tau+ mice 
showed significant decreased in synaptophysin expression (p < 0.001), CypD KO/Tau+ mice did 
not. CypD KO/Tau+ mice showed significantly elevated levels of synaptophysin when compared 
to Tau+ mice (p < 0.01). Fig. 3.10A/B 
 
Figure 3-10: Synaptophysin in CypD Modified AD Mice 
At six months, Tau+ mice show significantly depressed synaptophysin expression. Tau+/CypD 
KO mice have normalized synaptophysin expression. N = 3-5 *** p < 0.001 vs wild type, ## p < 
0.01 vs Tau+/CypD KO.   
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3.12 Mitochondrial electron transport chain activity loss in a tau-induced model of Alzheimer’s 
disease with CypD knock out 
 Mitochondrial function was assessed with an assay of Complex I. Tau+ mice showed a 
decrease in Complex I activity (p < 0.01), while CypD KO/Tau+ mice did not. CypD KO/Tau+ 
mice showed significantly increased Complex I function when compared to Tau+ mice (p < 0.05). 
(Fig. 3-11) 
 
Figure 3-11: Mitochondrial Complex Activity in CypD Modified AD Mice 
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At six months, complex I shows significantly depressed activity, but Tau+/CypD KO mice show 




3.13 Gross locomotion in a tau-induced model of Alzheimer’s disease with CypD knock out 
 Gross locomotion was assessed to determine if mice showed relative health problems or 
differences in motion pattern across genotypes. No changes were detected at 6 or 12 months of 
age. (Fig. 3-12) 
 
Figure 3-12: General Locomotion in CypD Modified AD Mice 
General locomotion is not affected by CypD or Tau expression at six or twelve months.  
75 
 
3.14 Anxiety-like behavior in a tau-induced model of Alzheimer’s disease with CypD knock out 
 Significant anxiety-like behavior, as measured by decreased time spent in the center, was 
identified in 6-month (Fig. 3-13A) and 12-month (Fig. 3-13B) Tau+ mice (p < 0.01). At both time 
points, CypD KO/Tau+ mice showed less anxiety-like behavior than the Tau+ mice (p < 0.001). 
CypD KO mice showed no significant differences from wild type mice in time spent in the center 
in either 6 or 12-month mice. This was in line with our previous findings that CypD KO prevented 
age induced cognitive impairments at 12 months. 
 
Figure 3-13: Anxiety-like Behavior in CypD Modified AD Mice 
At both 6 and 12 months, Tau+ mice show decreased time in the center of the arena. CypD 
KO/Tau+ mice, however, showed no decrease at six (A) or twelve (B) months. n = 11-19 ## p < 
0.001 wild type vs Tau+, ** p < 0.01 Tau+ vs Tau+/CypD KO  
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3.15 Daily task performance in a tau-induced model of Alzheimer’s disease with CypD knock out 
 Daily task performance was used to assess the long term and working memory of the mice. 
At six months (Fig. 3-14A), there Tau+ mice showed significant decreases in nesting activity (p < 
0.001) which is continued with 12-month-old mice (p < 0.001) (Fig. 3-14B). CypD KO mice show 
significant increased nesting activity when compared to Tau+ mice at both time points (p < 0.001). 
CypD KO mice, in line with our previous findings, do not show any impairment in nesting activity 
when compared to wild type mice. 
 
Figure 3-14: General Locomotion in CypD Modified AD Mice 
At both six and twelve months, Tau+ mice show significant decreases in nesting activity. CypD 
KO/Tau+ mice, however, do not have significant impairments in nesting activity. A. n = 6-16 B. 




3.16 AKT signaling in a tau-induced model of Alzheimer’s disease with CypD knock out 
 To assess mechanisms by which HPT might be interacting with CypD, we measured AKT 
signaling. AKT becomes activation upon phosphorylation (pAKT). pAKT then phosphorylates 
and inactivates GSK3β. 
At three months (Fig. 3-15A), there were no significant changes in wild type and Tau+ 
mice for AKT signaling. However, at six months (Fig. 3-15B), there was a significant decrease in  





Figure 3-15: AKT Activity in CypD Modified AD Mice 
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Data is presented as phosphorylated protein normalized to the total protein and actin; data is 
normalized to wild type levels. At three months, there is no significant change in Tau+ mice in Akt 
signaling. At six months, CypD+ mice have high levels of active Akt, while CypD+/Tau+ mice 
have significantly decreased levels of active Akt. n = 3-6 * p < 0.05 vs wild type ** p < 0.01 vs 




3.17 GSK3β signaling in a tau-induced model of Alzheimer’s disease with CypD knock out 
Based on the lack of change in Akt signaling at three months, we only examined 6-month-
old mice for GSK3β activity. GSK3β signaling was measured to assess the downstream effects of 
changes in Akt signaling. pAkt inhibits GSK3β by phosphorylating the Ser9 inhibitory site. 
GSK3β activity can be identified by looking at two phosphorylations: p-Ser9 and p-Tyr216. 
Phosphorylation at serine 9 is inhibitory while phosphorylation at tyrosine 216 is an activation site 
[330]. Phosphorylation at these sites is not mutually exclusive, so conclusions must be drawn by 
looking at both sites [331]. 
 At 6 months, p(Try216) GSK3β showed significant increases in the CypD OE/Tau+ mice 
(p < 0.05) (Fig. 3-16A). This change was not seen in the CypD OE or the Tau+ mice. P (Ser9) 
GSK3β showed significant increases in CypD OE mice (p < 0.01), while showing reductions in 
both Tau+ mice and CypD OE/Tau+ mice (p < 0.05) (Fig. 3-16B). 
 
Figure 3-16: GSK3β Activity in AD Mice 
At six months, CypD+/Tau+ mice show significant increases in expression of active GSK3β. 
Tau+ and CypD/Tau+ mice both show decreased expression of inhibitory GSK3β. CypD+ mice 
showed significant increases in inhibitory GSK3β. n = 5-7 * p < 0.05 Wild type vs CypD+/Tau+, 




Chapter 3 Interim conclusion 
 These experiments demonstrate that CypD has a significant impact on the AD phenotype 
in a tau-induced model of AD. 
 CypD OE increased cognitive dysfunction, while CypD KO preserved cognitive function 
in AD models. This was supported by molecular experiments that found that CypD OE increased 
levels of HPT, while CypD KO decreased HPT levels. Further, CypD OE increased synaptic and 
neuronal loss while CypD KO ameliorated these losses. Finally, CypD OE increased loss of 
mitochondrial function while CypD KO supported mitochondrial function. 
 These experiments also suggest a signaling pathway that is affected by the combination of 
HPT and CypD. Akt, which acts as an inhibitor of GSK3β, was inhibited in the CypD OE/Tau+ 
mice (Figure 3.16). GSK3β inhibition was severely decreased in the CypD OE/Tau+ mice and its 
activation was significantly increased. As was described in the introduction, active GSK3β can 
translocate to the mitochondrial matrix where it directly interacts with CypD to increase opening 
of the mPTP.  
 Overall, these results suggest a possible synergistic interaction by which CypD expression 
worsens the tau-induced AD phenotype, and in turn, the increase HPT modifies signaling pathways 




Chapter 4 Inhibition of CypD as a Therapeutic Target for Alzheimer’s disease 
 Due to the success of CypD KO in ameliorating the Tau+ induced AD phenotype and prior 
studies identifying CypD KO as a strong ameliorating factor in the Aβ induced AD phenotype [23, 
230, 231], we chose to pursue CypD as a target for drug development. The studies in this chapter 
are split between C-9, a compound we have published on, and a novel compound which is an 
analog of C-9. For this dissertation, the analog will be called SY1. 
 Experiments in this chapter used cells and the P301S mice described previously. For the 
cell experiments SK-N-SH cells were used. In the in vivo pharmacology studies, mice were given 
a daily intraperitoneal injection of the CypD inhibitor or a vehicle control starting at four months 
of age. Testing began at six months of age. 
 These experiments were conducted to test the sub-hypothesis presented in Schematic 4. 
Namely, that inhibition of CypD can prevent phosphorylated tau induced mitochondrial failure 
and the resulting synaptic and cognitive loss. 
 
Schematic 4: Sub-hypothesis for Chapter 4 
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4.1 CypD inhibitor structure 
 Our lab developed a series of compounds and C-9 was the best compound to come out of 
this screen [232] (Fig, 4-1). Further screening developed a secondary compound that was used for 
these experiments, but knowledge of that structure is currently restricted until patent protection is 
acquired. 
 
Figure 4-1: Structure of CypD Inhibitor 
The structure of C-9 was created based on molecular modeling using the structure of CypD. A 
newer, modified version of this structure was used in these studies.   
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4.2 Effectiveness of CypD inhibitor 
 C-9 was tested for toxicity using SK-N-SH cells in a cell viability assay. Additionally, C-
9 was tested in a calcium swelling assay to confirm its effect on the mPTP opening [232]. 
 In the cell viability assay, there were no significant impacts on viability at doses up to 100 
μM. No changes in cell morphology were seen with 100 µM C9. (Fig, 4-2)  
 In the mitochondrial swelling assay, three controls were used: (1) A no Ca2+, no C-9 control 
provides a baseline for swelling (black triangles), (2) a Ca2+ added, no C-9 control provides a 
maximum swelling (red icons), (3) a Ca2+ and CsA control provides a control for CypD inhibition 
(black squares).  
In a dose-dependent manner, C-9 reduced mitochondrial swelling from 10 μM to 100 μM. 
(Fig, 4-3). C-9 treated cells (green, purple, and yellow icons) showed significantly less swelling 






Figure 4-3: A calcium induced swelling assay of C-9 in isolated mitochondria 
Isolated mitochondria were exposed to 2 µM of calcium which induced swelling in untreated 
mitochondria. CsA was used as a control to inhibit CypD and prevent swelling. In a dose 








Figure 4-2: Functional Testing of CypD Inhibitor 
C-9 was tested in a cell viability assay in SK-N-SH cells. No cell death was detected at any dose 
tested.  
C-9 Treatment (μg/μL) 
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4.3 Inhibition of Cyclophilin D in an Aβ 
 The effect of C-9 on mitochondrial function was assessed using an ATP assay in 
conjunction with Aβ oligomers. Aβ caused a significant decrease in ATP (p < 0.01) and C-9 dose-
dependently increased ATP production in the presence of Aβ (p < 0.01). (Fig, 4-4A) 
 In an Aβ-induced cell death assay, Aβ caused significant cell death (p < 0.01) and  C-9 




Figure 4-2: Functional Testing of CypD Inhibitor in AD Cell Model 
C-9 prevents Aβ induced ATP depletion (A) and Aβ induced cell death in a dose dependent 




4.7 Mitochondrial complex activity in tau-induced Alzheimer’s disease with CypD inhibitor drug 
Mitochondrial complex activity was tested to assess mitochondrial function. Complex I 
was looked at due to its role in establishing the proton gradient across the inner membrane. 
Complex IV was chosen due to its role as the rate limiting step in the electron transport chain. 
Complex I was significantly reduced in Tau+ mice at 6 months when compared to wild type mice. 
However, Tau+ mice treated with SY1  showed ~60% recovery when compared to wild type. 
Complex IV activity was also lower in Tau+ vehicle treated mice. In Tau+ mice treated with the 
SY1, complex IV activity was ~80% recovered. 
 
Figure 4-3: Effect on mitochondrial function of CypD inhibitor on Tau+ mice 
Six-month-old vehicle-treated mice showed significant reduction of complex I and IV activity 




4.8 Gross locomotion in tau-induced Alzheimer’s disease with CypD inhibitor drug 
 Gross locomotion was measured with the SY1 in wild type and Tau+ mice at six months. 


























































Figure 4-4: General Locomotion with Treatment by a CypD Inhibitor 
Neither genotype nor treatment with the CypD inhibitor affected general locomotion.  
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4.9 Anxiety-like behavior in tau-induced Alzheimer’s disease with CypD inhibitor drug 
 Anxiety-like behavior was measured in open field to assess cognitive impairment in Tau+ 
mice treated with SY1. Tau+ mice showed significantly decreased time spent in the center of the 
assay indicating significant anxiety-like behavior (p < 0.001). However, treatment with SY1 
completely ameliorated these defects (p < 0.001) (Fig, 4-5). There was no significant difference 
between wild type mice treated with vehicle and Tau+ mice treated with the SY1.  
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Figure 4-5: Anxiety-like Behavior when Treated with a CypD Inhibitor 
Six-month-old vehicle-treated Tau+ mice showed significant reduction in time in the center 
compared to wild type mice. Tau+ mice treated with the CypD inhibitor showed no change in 
anxiety-like behavior.  
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4.10 Daily-task performance in tau-induced Alzheimer’s disease with CypD inhibitor drug 
 A nesting assay was employed to measure memory and task performance in Tau+ mice 
treated with a CypD inhibitor. Tau+ mice showed significantly impaired ability to build nests (p < 
0.001) indicating a significant impairment of memory. Tau+ mice treated with a CypD inhibitor 




Figure 4-6: Daily Task Performance when Treated with a CypD Inhibitor 
Six-month-old Tau+ mice showed significant decreases in nesting activity. Tau+ mice treated with 
the CypD inhibitor did not show any such deficits. 
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Chapter 4 Interim conclusions 
 These studies demonstrate the effects of small molecule CypD inhibitors for the 
amelioration of AD symptomology. Our inhibitor is effective at preventing mPTP opening and 
preserving mitochondrial function. The CypD inhibitor is effective at preventing death induced by 





Chapter 5 Conclusions 
Chapter 2: The Role of CypD in Aging Mice 
These experiments first demonstrated a cognitive decline in non-transgenic aging mice. 
We analyzed sex differences on several behavioral tests as mice age. Given new research 
requirements to include female animals, it is likely that these differences will become more 
important. Historically, researchers have underestimated the differences between males and 
females and chosen to only study males. 
In the open field paradigm, male and female mice maintained similar general locomotion 
and motion patterns at all age points. Many behavioral tests, such as elevated plus maze, object 
exploration, and social recognition tests, rely on the premise that mice are not experiencing 
difficulty moving or showing different explorative patterns. However, these behavioral tests do 
not allow for an easy assessment of general locomotion patterns, as demonstrated here. Using a 
reliable method of identifying gross motor defects will improve the accuracy of other behavioral 
tests and ensures that behavioral tests as mice age will likely reveal useful, disease-relevant data 
rather than artifacts of the aging process. 
Female mice demonstrate higher levels of anxiety-like behavior with aging. This is of 
particular importance to research in many aging diseases, such as Alzheimer’s disease, which are 
more common in women. Knowing that male mice do not naturally display increases in anxiety-
like behavior is also important, given that aging diseases such as Parkinson’s disease and type 2 
diabetes are more common in men. 
 Daily task performance is a useful metric of working and long-term memory. Mice build 
nests for thermoregulation, meaning that it is not a sex-specific behavior, and is learned as a natural 
behavior when the mice are pups. This makes nesting activity a particularly good measure of skills 
that mice naturally have, rather than one that researchers teach to them, like lever pulling or maze 
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running. This test found declines earlier than other paradigms have found memory impairments 
due to its specific design. A high-quality nest will use all of the available material shredded, 
organized into a region less than ¼ the area of the cage, and built up high enough to cover the 
mouse entirely. Three-month-old mice, whether male or female, rarely fail to build nests fitting 
this description. However, by 12 months of age, many mice (8/13) fail to utilize the entire nestlet, 
and none build nests of sufficient height. This is indicative of a failure of memory or performance 
of a nesting task learned as pups. This trend is continued in 24-month-old mice, where only 6/23 
mice built proper nests. Based on data from the open field paradigm showing that 24-month-old 
mice are capable of similar gross motor, we interpret this to mean that aging mice start to show 
subtle memory failures. 
 Having discovered this robust age-dependent cognitive decline, we sought to determine a 
mechanism by which this may occur in non-transgenic mice. Mitochondrial failure with age and 
neurodegeneration has been demonstrated in several models [332-334]. Specifically, with age 
there is a decline in mitochondrial respiratory chain complex activity and an increase in mutations 
of mitochondrial genes [335-339]. This leads both to a loss of ATP production as well as an 
increase in ROS [334, 340-342]. Loss of mitochondrial function is even more pronounced at the 
synaptic level, where losses of energy can lead to synaptic loss [343-346]. We hypothesized that 
mitochondrial failure was the root cause of this cognitive impairment. 
We identified increased ROS production in both males and females with age. This was 
accompanied by reduced activity in Complex I and Complex IV of the mitochondrial ETC. These 
correlative results supported the hypothesis that aging mice were experiencing cognitive decline 
as a result of mitochondrial failure. However, further experimentation would be necessary to 
definitively prove causation. 
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We further hypothesized that the mitochondrial failure was directly related to the activity 
of CypD, given its proposed role in neurodegeneration that was discussed at length in the 
introduction. We first tested this hypothesis by measuring levels of CypD and determining that 
aging mice showed increased expression of CypD. Then, CypD OE and CypD KO models were 
used to manipulate the levels of CypD to test a causative role in cognitive impairment.  
We determined that CypD OE mice showed a phenotype that we termed “early aging”, in 
which they showed cognitive impairment at an earlier age than non-transgenic mice. The 
significant increased expression of CypD induced an anxiety-like phenotype in males and females 
as early as six months. Additionally, by six months, CypD OE males and females were showing 
declines in nesting activity. Most interestingly, CypD OE reduced life expectancy of mice to about 
15 months, making them unavailable to study at the latest time points used for these aging studies. 
CypD KO mice were resilient to cognitive impairments with age. They did not show an 
anxiety-like phenotype in the open field paradigm, and were still building near perfect nests at 24 
months old. While no formal survival curve was done, these mice long out lived their age matched 
controls. 
Studies in the lab demonstrated that CypD KO mice had better mitochondrial function and 
less reactive oxygen species. These studies also identified increased buffering of calcium and 
membrane potential more resistant to ROS induced failures.  
 Taken together, these studies indicate a strong role for CypD in cognitive failure in aging 
animals. However, these studies were limited by several factors that should be corrected in future 
study. First, synaptic loss via imaging was not assessed in these mice. While we hypothesize that 
synaptic loss is the tie between mitochondrial failure and cognitive impairment, this was not 
proven here. Second, given the ample evidence that synaptic and somatic mitochondria are 
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separate pools with separate characteristics and different sensitivities to stress [345], these two 




Chapter 3: The Role of CypD in Alzheimer’s disease Mice 
 Given the role of CypD in Aβ models of AD, we hypothesized that tau-induced AD would 
be equally affected by CypD. Due to the lack of success in drug trials targeting Aβ pathways alone, 
identifying an effective target in both Aβ pathology and tauopathies would substantially improve 
the chances of success of a compound in treating AD. 
 These studies were divided into two sections: those utilizing CypD OE to model a more 
severe AD pathology and those utilizing CypD KO to model the potential therapeutic effect. CypD 
OE mice were crossed into the P301S tau mice. The double transgenic mice represent severe AD 
phenotype when compared to the Tau+ mice; wild type and CypD OE alone mice served as 
controls. Similarly, CypD KO mice were crossed into P301S tau mice to create a therapeutic model 
when compared to the Tau+ mice with wild type and CypD KO mice serving as controls. 
 CypD OE/Tau+ mice showed more significant CypD accumulations than CypD OE alone 
mice, as well as increased levels of HPT when compared to Tau+ mice. These results indicate 
more severe AD pathology. Additionally, CypD OE/Tau+ mice show more significant depressions 
of mitochondrial complex activity. CypD OE/Tau+ mice also showed more significant decreases 
in synaptophysin and neuronal tubulin, indicating a loss of both synaptic structures and neurons. 
CypD OE/Tau+ mice also showed more significant cognitive impairments, with increased levels 
of anxiety-like behavior and decreased daily task performance. Overall, these results suggest that 
increased expression of CypD causes an earlier onset of AD with worse symptoms. 
 CypD KO/Tau+ mice showed an amelioration of every tested phenotype of AD. Tau 
expression, while very high in the Tau+ mice, was significantly reduced with knock out of CypD. 
CypD KO/Tau+ mice also showed increased mitochondrial ETC activity when compared to Tau+ 
mice. This was accompanied by an increase in synaptophysin, indicating that CypD KO in Tau+ 
mice increases the preservation of synaptic structures. As predicted by our hypothesis, CypD KO 
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prevented tau-induced cognitive deficits, with no increase in anxiety-like behavior and sustained 
daily task performance behaviors.  
 These experiments confirm the hypothesis laid out in Schematic 1. CypD OE is sufficient 
to induce an AD phenotype in some regards: increased mitochondrial failure, increased synaptic 
loss, increased neuronal loss, and reduced cognitive function. However, CypD OE was not 
sufficient to induce HPT. When combined with P301S tau, CypD OE did induce a significant 
increase in HPT, as well as more significantly increasing the other markers of AD measured. 
 CypD expression was also shown to be necessary for the AD phenotype. When P301S 
mice had CypD knocked out, there was no significant increase in HPT, no mitochondrial failure, 
no synaptic loss, and no cognitive failure. 
 We looked further into mechanisms that may connect the increases in phosphorylated tau 
to increased mitochondrial damage mediated by CypD. We identified the Akt/GSK3β pathway as 
potentially important, laid out in Schematic 5. Inhibition of Akt activity results in more active 
GSK3β, which can then be translocated to the mitochondrial matrix. As discussed previously, 
active GSK3β can phosphorylate CypD, predisposing mPTP opening. Our results indicate an 
inhibition of Akt in six-month-old Tau+ mice and CypD+/Tau+ mice. This extended into an 
increase in active GSK3β in these same genotypes. We interpret this to indicate that the increased 
tau expression reduced Akt activity, which is in line with previous studies [347].  
 
Schematic 5: The AKT/GSK3β pathway. 
 Surprisingly, the CypD OE genotype alone showed an extreme increase in Akt activity, 
indicating a pathway by which CypD can alter Akt signaling. Several lines of research indicate 
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that there is a mechanism of self-regulation in which opening of the mPTP can suppress Akt 
signaling [348]. In this case, it is possible that this suppression of Akt reduces mPTP opening, 
resulting in a less dramatic cognitive decline than one may predict. 
 One may wonder why CypD OE mice and Tau+/CypD OE mice show differential 
regulation of the Akt/GSK3β signaling. In this case, we can conclude that Tau OE is the dominant, 
harmful phenotype.  
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Chapter 4: Inhibition of CypD as a Therapeutic Target for Alzheimer’s disease 
 These results demonstrate the effects of a CypD inhibitor developed in our lab. While 
previous structures of this inhibitor have been published and are referenced in this dissertation, 
this is the first evidence of a new, effective compound.  
 The CypD inhibitor used in these studies were developed via a system of intelligent 
modeling based on improved structures developed in experiments with collaborators in medicinal 
chemistry.  
In molecular binding assays, this small molecule successfully binds to CypD and inhibits 
its activity. The levels of inhibition are better than that of previous compounds tested by our 
laboratory and other research groups. Further, the compound is non-toxic to cells even at large 
doses, and can inhibit Aβ induced cellular death and Aβ induced mitochondrial failure. 
This compound was well tolerated in mice, although no explicit toxicology tests were 
conducted. In mice, the SY1 did not prevent the accumulation of HPT, further supporting that 
CypD is a target site for ameliorating cognitive deficits induced by tau. Mitochondrial function 
was also preserved in Tau+ mice treated with the CypD inhibitor. This translated into preserved 
cognitive function. Tau+ mice treated with the CypD inhibitor did not show an anxiety-like 
phenotype that is associated with Tau+ mice at six months and retained their daily task 





 The work presented herein suggests that CypD represents an excellent target for continued 
investigation in AD and age-related cognitive decline. Genetic ablation of CypD is sufficient to 
prevent age related cognitive decline as well as the appearance of AD in mice. Pharmacological 
inhibition of CypD prior to the appearance of neuronal loss similarly prevents cognitive symptoms 





Chapter 6 Future Directions 
Future studies in aging mice 
 Based on the studies conducted in Chapter 2, the use of the SY1 as used in Chapter 4 for 
the amelioration of age-induced cognitive dysfunction is warranted. By creating a dosing curve, 
in which animals begin dosing with the inhibitor at 6, 12, 18, or 20 months and are tested for 
cognitive dysfunction at 24 months, an essential time point could be determined for the 
preservation of cognitive function in non-transgenic aging mice. Once said time point is 
determined, molecular changes with the CypD inhibitor could be determined. ROS and 
mitochondrial ETC activity are obvious targets of intrigue. However, new technology available, 
including a 2-photon microscope, could allow for the tracking of synaptic formation and loss over 
the time course of drug administration [349]. Based on our studies tying mitochondrial failure to 
synaptic loss, understanding the specific changes of the neural network in aging could explain how 
mitochondrial failure leads to cognitive impairment. Further, studying these same networks under 
the effects of CypD inhibition could reveal probative information about how this compound is 
working to reverse cognitive impairment. 
 Further mechanistic data could be gathered on the cognitive changes observed in aging 
mice. Based on changes to GSK3β signaling seen in AD mice, this pathway should be investigated 
in aging mice. We would expect that aging mice would show decreased Akt activity, as measured 
by decreased p-Akt on a western blot, and increased GSK3β activity, as measured by increased 
p(tyr216)GSK3β and decreased p(ser9)GSK3β. 
 Additionally, measuring calcium induced mitochondrial swelling in an age dependent 




Future studies in Alzheimer’s disease mice 
P301S Tau mice are only one model of tau-induced AD. Testing the effect of CypD in 
another model would strengthen hypothesis that CypD and HPT are related. One model that might 
be particularly beneficial for this is the rTGTauEC model, which is a slow developing model that 
shows HTFs, synaptic and neuronal loss, and impaired cognitive functioning. These studies would 
confirm that the relationship between CypD-mPTP opening and HPT accumulations.  
While this study, combined with previous work in the lab, identifies CypD as a therapeutic 
target in Tau-induced AD and Aβ-induced AD, CypD has not been tested in a mouse model 
containing both Aβ and HTFs.  
Further establishing the effects of CypD Inhibition 
While this compound exerts its effects through inhibition of CypD, we would like to 
determine whether there is a systematic effect taking place outside of the mitochondria. 
Specifically, we would like to identify changes in signal transduction that may be occurring in the 
Tau+ and wild type mice treated with the CypD inhibitor. CypD OE mice showed changes in Akt 
and GSK3β activity, indicating that there is an effect of CypD expression or activity on signaling 
pathways. Thus, we hypothesize that there are likely changes in this signaling pathway that have 
not been identified. 
Previous studies have not found an effect of CypD KO on LTP, an important indication 
that CypD KO does not impair neuronal signaling. For that reason, we hypothesize that there 
would be no negative impact of CypD inhibition on neuronal signaling. However, our lab has not 
tested LTP in the Tau+ mice, and doing these experiments could help to bolster the interpretations 
of the data presented herein, that CypD KO can improve learning and memory. 
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Toxicity studies for the CypD Inhibitor 
While toxicity studies are not the priority with this compound, given our goal of 
establishing this compound as a candidate for clinical trials, toxicity testing is still a needed 
component. The earlier proposed time point studies could double as important toxicology studies 
necessary for this compound to move forward. While no obvious toxicity was registered in any 
animals in which this compound was used, and the compound was found non-toxic in very high 
doses in cell culture, formal toxicity studies will be necessary for any effort to move the inhibitor 
into clinical trials.  
There are multiple protocols for assessing toxicity of compounds [350]. While most 
protocols demand both a rodent and non-rodent species for toxicity studies, the first step would be 
to complete rodent-based studies in mice. Historically, single dose acute toxicity has been 
determined by administering a single dose of variable amount to a group of animals and assessing 
the reaction over 14 days. LD50, the dose toxic to 50% of subject animals, has largely been replaced 
with metrics that require fewer animals.  
The up-and-down (UPD) approach is most commonly used by regulatory agencies. UPD 
protocols give single animals doses sequentially every 48 hours. Each subsequent dose is double 
the former dose. If an animal dies, an intermediate dose, one between the non-lethal and lethal 
dose, is chosen to start upon selection of a new animal. 
Repeated dose toxicity tests take longer, a minimum of 28 days. After the 28 days, nearly 
all of the organs are retained for histological examination. A subgroup must be analyzed at no later 
than 14 days for immunotoxicity. 
Sub chronic toxicity is measured by testing organs after 90 days of administration and 
chronic toxicity is a measure longer than 90 days. Mice sacrificed after the long-term study of the 
effect of the compound on cognitive impairment could be used for these chronic (mice dosed from 
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6, 12, or 18 months) and sub chronic (mice dose from 20 months) conditions. Many protocols 
recommend assessment of behavioral protocols as well. By using these mice in studies to test our 
hypotheses and toxicity studies, we would reduce the overall number of mice required in moving 
this compound from pre-clinical to clinical work. 
 Beyond toxicity testing, further time point testing is necessary. In these studies, mice were 
dosed at four months. This time point is after the elevation of HPT and after mild mitochondrial 
failure, but before any synaptic or neuronal loss. Behavior studies were run at six months, after 
which, animals were sacrificed and used for molecular studies. We did not confirm if the CypD 
inhibitor was effective in AD mice over a longer period of time.  
The Role of CypD in Other Neurodegenerative Diseases 
Given the important role of CypD in cognitive impairment and neurodegeneration 
established in these experiments, there is likely a role of CypD in other neurodegenerative diseases. 
Huntington’s disease 
 Huntington’s disease (HD) is an autosomal dominant disease characterized by a pattern of 
CAG nucleotide repeats [351]. A person having more than 40 repeats will be diagnosed with HD, 
and the number of repeats is proportional to the age of onset of the disease; the highest reported 
number of repeats is about 250 [352]. HD leads to the accumulation of huntingtin protein [353]. 
HD leads to the death of neurons, most characteristically GABAergic neurons [354], which results 
in a movement disorder with dementia [355]. 
 Huntingtin is a cytosolic protein that has a role in vesicular transport [356]. Mutant 
huntingtin disrupts axonal transport [357], N-methyl-D-aspartate receptor (NMDAR) signaling 
[358], and mitochondrial function [359-361]. Mitochondria from HD patients and models undergo 
increased fission. Additionally, huntingtin can be found in the matrix of mitochondria. 
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HD is characterized by calcium dyshomeostasis [362]. Mitochondria isolated from patients 
with HD or from animal models of HD show disrupted calcium uptake capacity in which the mPTP 
opens at a much lower concentration of calcium compared to healthy controls [363-367]. In HD 
patients, CypD was upregulated in a progressive, time dependent manner that correlated to the 
disease progression [361]. Upregulated CypD was also identified in BACHD mice that contain 97 
CAG repeats [359]. This irregularity in mPTP opening combined with the increases in CypD 
expression suggest a role of CypD with potential therapeutic effects to reduce mitochondrial loss 
and neuronal death.  
 CypD KO in an R6/2B model of HD increased calcium buffering capacity, indicating a 
desensitization of the mPTP. However, CypD KO did not reduce weight loss or improve 
behavioral phenotypes measured for HD. Most importantly, R6/2B CypD KO mice did not survive 
longer than their R6/2B counterparts [368]. One possible interpretation of this data is that the 
mPTP is not involved in the HD phenotype. However, mitochondrial function and mitochondrial 
axonal transport were not assessed in the CypD KO mice. Mutant huntingtin protein impairs 
mitochondrial trafficking to the synapse, which may mask the effect of reduced mPTP opening. 
CypD therapeutics may be a necessary part of a drug regimen that also addresses trafficking 
dysfunction. R6/2B mice have a very rapid onset of HD like symptoms, and have a track record 
of poor predictive validity [369], which may warrant further testing in a different HD model. 
Amyotrophic Lateral Sclerosis 
 Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease that is fatal within 
five years of symptom onset [370]. ALS is characterized by muscle weakness and loss of motor 
control [370], which is caused by degeneration of lower motor neurons in the cerebral cortex and 
spinal cord [371]. Ten percent of ALS cases are familial with a strong genetic component while 
90% occur sporadically with an onset after 55 years of age [372].  
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 ALS patients and models show significant mitochondrial morphology abnormalities [373]. 
Mitochondria from end plates of ALS patients showed increased mitochondrial volume [374], 
which has more been associated with mPTP opening. Further, mitochondria isolated from ALS 
show reduced ETC protein levels and activity [375]. Tissue from ALS patients reveals significant 
increases in ROS [376]. One of the familial mutations that causes ALS is in the mitochondrial 
super oxide dismutase (SOD1) gene [377], which further links ALS to mitochondrial dysfunction. 
The only current FDA treatment for ALS is a glutamate blocker trade name Riluzole; glutamate 
toxicity is often the result of increased calcium and the inability of mitochondria to buffer it.  
 Apoptosis in ALS is driven by p53 which, as previously discussed, acts as a regulator of 
CypD driven mPTP opening [378]. CypD expression levels are increased in models of ALS [376], 
which could explain the increased mPTP opening that leads to mitochondrial swelling at end 
plates. Further, CsA improved outcomes for ALS mouse models [379, 380], although, given the 
immunosuppressive effects of CsA, it is not possible to fully attribute that success to CypD 
inhibition and reduced mPTP pore opening. CsA is currently in phase II clinical trials for treatment 
of ALS under the trade name Mitoguard. In G93A high-mSOSD1 mice, a model of ALS, CypD 
KO delayed the onset of ALS-like symptoms and slowed the progression of the disease after onset 
[381]. In the same model, CypD KO reduced ROS levels [376]. In a second model of ALS based 
on SOD1 mutations, CypD KO improved calcium buffering capacity, increased ATP synthesis, 
and reduced mitochondrial swelling, while also reducing protein aggregation in the cytosol [382].  
 Based on the excellent results in CypD KO mice, further study with CypD specific 
inhibitors is indicated in ALS. 
Parkinson’s disease 
 Parkinson’s disease (PD) is a neurodegenerative disorder characterized by bradykinesia. 
PD is most commonly associated with tremors [383] . Neuronal loss is most profound in the 
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dopaminergic neurons of the substantia nigra, but is apparent in other brain regions as well [384]. 
Less than 10% of PD is familial, with the majority having a sporadic onset after the age of 50 
[385]. Molecularly, PD is characterized by the formation of Lewy bodies in the cytoplasm, mostly 
composed of α-synuclein [386, 387].  
 α-synuclein aggregation has been proven to directly cause the opening of the mPTP which 
can be blocked via CsA [388], indicating that α-synuclein likely works through CypD. In a model 
of PD in which C57BL/6 mice express human A53T-mutant α-synuclein, CypD KO delayed the 
onset of PD-like symptoms and extended lifespans [389]. In a PD model based on mutation of the 
motor neuron desecration 2 (MND2) gene, mice are more sensitive to mPTP opening. However, 
CypD KO did not improve outcomes [390], indicating that the PD model of choice will be 
important for further characterization of the role of CypD and mPTP opening. Human derived cell 
lines may help to clarify discrepancies identified here. 
Final Conclusions 
 CypD has roles in many neurodegenerative diseases, likely including some that are not 
discussed here.  Further development of SY1 into a feasible therapeutic option, as well as further 
study of the role of CypD and mitochondrial dynamics in the brain, will be likely to have a high 
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